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Abstract 
Hepatitis B vims (HBV) infection, which is a major risk factor for the development 
of hepatocellular carcinoma (HCC), is endemic in many regions of the world 
including Southeast Asia, Sub-Saharan Africa, China and Hong Kong. The HBx gene 
of HBV has been postulated to play an important role in the viral pathogenesis by 
transactivating viral and critical cellular genes. To further elucidate the structure and 
function of the HBx protein, HCC tissues were analyzed for HBx expression by 
immunohistochemical staining. Strong HBxAg expression was found in the cirrhotic 
tissues adjacent to the HCC while low or undetectable expression was found in the 
tumors. On the other hand, the HBx gene from the HCC，adjacent cirrhotic，non-
tumorous tissues and sera of hepatitis patients were found to contain multiple 
numbers of mutations in various regions. Hot spot mutations occurring at amino 
acids 130 and 131 of the HBx protein was previously reported to be commonly found 
in HCC and its surrounding cirrhotic tissues but not from the sera of chronic hepatitis 
patients without HCC. However, we have found that such mutations are also 
commonly found in the sera of chronic hepatitis patients without HCC, indicating 
that its role may be in the preneoplastic stages. The HBx sequences from the HCC 
were then fused with the reporter gene GFP (Green Fluorescent Protein) and the 
chimeric genes were transfected into HeLa and HepG2 cells. Both the wild type and 
mutated HBx fusion proteins were found to localize in distinct foci in the cytoplasm 
of the transfected cells and gradually migrate towards the peri-nuclear region. The 
HBx protein inhibited cell growth and induced cell death in the transfected cells. 
These data indicate that the major site(s) of action of the HBx protein is in the 
cytoplasm and/or the peri-nuclear region, and that HBx may play a role in liver 





















Abbreviations Used in this Thesis 
A260 Absorbance at 260 nm 
A280 Absorbance at 280 mn 
A330 Absorbance at 330 nm 
AEC Aminoethyl carbazoyle 
APES 3-Aminopropyl-triethoxysilane 
APH Aqueous pre-hybridization / hybridization 
ATP Adenosine 5，-triphosphate 
bp Base pair 
Ci curie 
DAPI 4，，6-diamidino-2-phenylindole 
dATP Deoxyadenosine triphosphate 
dCTP Deoxycytidine triphosphate 
dGTP Doxyguanosine triphosphate 
D-MEM Dubelcco's Modified Eagle Medium 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
dNTP Deoxyribonucleoside triphosphate 
dTTP Deoxythymidine triphosphate 
FITC Fluorescein isothiocynate 
g Gravity 
HBs Hepatitis B virus s gene 
HBV Hepatitis B virus 
HBx Hepatitis B vims x gene 




PBS Phosphate buffered saline 
PCR Polymerase Chain Reaction 
RNAse Ribonuclease 
rpm Revolutions per minute 
SDS Sodium dodecyl sulphate 
SSC Sodium chloride / Sodium citrate (buffer) 
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Chapter 1 Introduction 
1.1 Hepatocellular Carcinoma 
1.1.1 Epidemiology 
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the 
world with an occurrence of at least 1 million new cases annually/ In China alone, 
approximately 100,000 people die from HCC annually? Worldwide, it is the seventh 
most common malignant tumor in males and the ninth in females/ The incidence of 
HCC in Hong Kong is 47 / 100,000 and prognosis is poor. Patients diagnosed with 
HCC usually die within months or even weeks, with a five-year survival rate of less 
than 5 
1.1.2 Geographical Distribution 
The incidence of HCC correlates with prevalence of HBV infection mainly 
concentrated around south-east Asian countries including Taiwan, Korea, Thailand, 
Hong Kong, Singapore, Malaysia, China and sub-Saharan Africa/，� In these areas, 
the rates of HBV infection range from 10 to 25 % and are maintained by either 
vertical transmission from mothers to infants or horizontal spread among young 
children below the age of 10? Compared with North America and Europe where 
incidence of HCC is 1-3 per 100,000 population^ Asia has a remarkably high 
incidence of 10-20 per 100,000 population.^ 
1.1.3 Sex and Age 
HCC is more common in males than in females regardless of geography/'^ although 
the ratio of incidence between the two sexes vary among regions. Generally speaking, 
the higher the incidence, the higher the male:female ratio,4 which may be attributed 
to hormonal and genetic factors/ '^  
The incidence of HCC generally increases with age, with a tendency to level off at 
older ages.i4 However, in high incidence countries, there is a shift of peak age 
towards the younger population. In most countries, the peak age is around 60, but in 
Mozambique, a country with high HCC incidence, the peak age is less than 30/ In 
Hong Kong, HCC has been reported in children as young as 2 years old.6 
I 1 
1.1.4 Et io logy 
1.1.4.1 Cirrhosis 
Cirrhosis is the underlying disease in over 80 % of patients with HCC. However, its 
role in HCC is still unclear. Cirrhosis is neither a pre-requisite nor an inevitable 
consequence of HCC development. Liver cell damage and regeneration may be the 
crucial oncogenic event, promoting selection and clonal expansion of transformed 
cells. 
1.1.4.2 Hepatitis B Virus (HBV) 
There is considerable evidence associating HBV infection with the development of 
HCC, although the exact mechanism by which HBV causes HCC remains unclear as 
other factors including age，sex, aflatoxin, smoking and alcohol may also be involved. 
HCC incidence is highest in countries where HBV infection is endemic. In low 
incidence areas, ethnic groups with high incidence of HCC are usually confined to 
those with high carrier rates of HBV.''^ Familial clustering of HCC is also found to 
be related with vertical transmission of HBV. Worldwide, more than 250 million 
people are chronically infected with HBV and have a 100-fold increased risk of 
developing HCC/ 
The presence of HBV antigens can be demonstrated in tumorous and non-tumorous 
tissues of patients with HCC. Integrated HBV DNA is also commonly found in 
tumors of both HBsAg-positive and negative patients with identical integration 
patterns, indicating clonal origin of malignant cells/ While the vims is frequently 
fragmented after integration, the HBx gene was often found to be intact, suggesting a 
role in hepatocarcinogenesis/ More details on the role of the hepatitis B vims and its 
Zgene in hepatocarcinogenesis will be discussed in Chapters 1.2 and 1.3. 
1.1.4.3 Hepatitis C Virus (HCV) 
Similar to HBV, the relative risk of HCC among chronic HCV carriers is about 100-
fold higher than non-carriers. HCV is an RNA virus, neither reverse transcribed nor 
integrated into the host genome. After acute infection, it takes about 30 years for the 
development of HCC through chronic hepatitis? Well-known and common modes of 
transmission include blood transfusion and use of intravenous drugs. 
Around 76 % of HCC cases in Japan, Italy and Spain and 30 to 50 % in the USA are 
associated with HCV infection.^'^ Currently, not much is known about the etiology of 
I 2 
HCV infection as a cause of HCC. One opinion is that HCV may promote HCC 
through cirrhosis, an important risk factor for this tumor. 
1.1 A.4 Dietary Aflatoxin 
Food products such as grains and peanuts are often contaminated with the fungus 
Aspergillus flavus in humid and sub-tropical regions such as Mozambique and 
Indonesia. This fungus produces two groups of aflatoxin: B” B?, Gj and G2. 
Aflatoxin Bj is the most hepatotoxic although to be carcinogenic, chronic exposure 
to the mycotoxin seems necessary.^ 
Rats fed with aflatoxin B^ developed HCC in a dose-dependent maimer while 
treatment of transgenic mice carrying integrated HBV DNA greatly enhanced the 
development of HCC over that of mice not treated with aflatoxin/^ Unfortunately, 
epidemiologic analysis in human populations is difficult as regions with aflatoxin-
contaminated food stuffs also tend to be endemic for HBV. However, the intake of 
aflatoxin Bi by ten villages in China has been shown to correlate with HCC mortality 
rates.ii 
Recently, aflatoxin was found to cause a G to T transversion in the third nucleotide 
of codon 249 of the p53 gene. Interestingly, all patients with HCC with p53 
mutations were also HBV-positive, suggesting that this vims or other hepatotoxic 
agents could be necessary pre-requisites for aflatoxin-mediated HCC. 12 
j 
1.1.4.5 Alcohol 
Alcohol does not have mutagenic properties and cannot be considered as a bona fide 
promoting agent for HCC. However, in alcohol-associated HCC, the effect is dose 
dependent and cirrhosis, with or without other etiologic factors such as HBV and 
HCV, seems to be the underlying cause. 
1.1.5 Molecular Basis of HCC 
1.1.5.1 Chromosomal alterations in HCC 
A comprehensive allelotype study done by Boige et al ^^ on 48 HCCs found frequent 
deletions in chromosome regions 8p (60 %), 17p (48 %), Ip (44 %), 4q (42 %)，16p 
(40 %)，16q (39 %)，6q (35 %), 9p (30 %) and 13q (29 %). These findings agree well 
with comparative genomic hybridization (CGH) analysis done by Marchio et al ^^ in 
50 HBV-associated primary HCC, who found frequent losses in chromosome regions 
I 3 
4q (70 %)，8p (65 %)，16q (54 %)，17p (51 %)，13q (37 %) and 6q (37 %). On the 
other hand, frequent gains were found in chromosome regions 8q (60%)，Iq (58 %), 
6p (33 %) and 17q (33%). These data suggest that both amplification of proto-
oncogenes and/or loss of tumor-suppressor genes may play a role in the 
carcinogenesis of HCC. Candidate genes whose loss or alteration may be related to 
hepatocarcinogenesis include E-cadherin on chromosome p53 on chromosome 
rip严 Rb at chromosome Platelet Derived Growth Factor (PDGF) Receptor p-
Like Tumor Suppressor on chromosome 8p ^^  and pl6 on chromosome region 
9p21.i7，i8 
1.1.5.2 Growth factors, proto-oncogenes and tumor-suppressor genes 
Chronic inflammation of the liver has been reported to induce expression of growth 
factors and cytokines, thereby promoting the clonal expansion of transformed cells.^ ^ 
These include: 1) direct mitogens such as hepatocyte growth factor (HGF), epidermal 
growth factor (EGF), transforming growth factor (TGF-a), acidic fibroblast growth 
factor (aFGF)，and hepatocyte stimulatory substance (HSS); 2) indirect or co-
mitogens including insulin, glucagon, norepinephrine, vasopressin, angiotensin II, 
vasoactive intestinal peptide (VIP); and 3) inhibitors such as transforming growth 
factor p (TGF-P), interleukin 1 (IL-1), interleukin 6 (IL-6) and leukemia inhibitory 
factor (LIF). 
Increased expression of proto-oncogenes such as c-fos, c-jun, c-myc, c-H-ras, 
c-met, 20 erbB ^^ and MAGE-1,^^ as well as decreased expression of tumor-suppressor 
genes including Rb，p53, and PML严 have also been reported. 
Although increased expression of the above growth-related genes are also found 
！ 
! during cirrhosis and liver regeneration and thus are not HCC specific, the resulting 
I 
altered cascades of growth signals within cells maybe one of the mechanisms leading 
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I 1.1.6 Situation in China and Hong Kong 
I 1.1.6.1 China 
I The overall prevalence of HBsAg in China is 9.8 %. Prevalence was found to be 





southern China (10.8 %) than in northern China (8.5 %). It is estimated that 60 % of 
all liver cancer deaths in the world occur in China.^^ 
1.1.6.2 Hong Kong 
A study in 1978-1979 on 16,334 subjects revealed that 42.9 % had evidence of past 
HBV infection and 9.6 % were HBsAg carriers, with carrier rate being higher in 
males (11.0 %) than in females (6.1 %)产 In the 1980s, over 11 % of women 
screened in antenatal clinics were carriers for HBsAg. This figure has dropped to 
around 10 % in recent years?-
Chronic hepatitis infection is the most common cause of chronic liver disease, 
cirrhosis and liver cancer in Hong Kong. In 1995，this group of diseases ranked 
fourth among causes of potential years of lives lost before 65/^ 
Liver cancer, the second most common cause of cancer deaths in Hong Kong (12.7 
%)，is the second most common cancer in males and the fourth in females.^^ In 1994, 
j 
1,800 new cases of liver cancer were reported to the cancer registry .26 There is male 
j predominance with a sex ratio of around 3:1 and onset being earlier in m a l e s ? 
I Although the crude death rates for liver cancer have shown marginal increase during 
j the past 25 years, which could be explained by the aging population, age-specific 
[ death rates (ages 35-44 and 45-54) have been decreasing in recent y e a r s ^ The reason 
I for this is unknown. 
j Among all liver cancers reported to the Hong Kong Cancer Registry, 65 % were 
HCC. Median survival time is short, ranging from a few weeks to a few months^ 
j Eighty percent of patients with HCC were found to be HBV carriers and 7 % were 
I HCV carriers,26suggesting the more important role of HBV in Hong Kong HCC than 
HCV. However, being less prevalent, HCV makes a proportionally greater 
I contribution. 
I 1.2 The Hepatitis B Virus 
I 1.2.1 Morphology 
The hepatitis B vims has a diameter of 42 nm with aVnm lipoprotein bilayer derived 
from the endoplasmic reticulum (ER) of the host. Inserted in this bilayer are 3 types 
i 1 1 
5 
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of HBV surface proteins with different sizes and degree of glycosylation: large 
hepatitis B surface protein (LHBs)，middle hepatitis B vims surface protein (MHBs) 
and small hepatitis B vims surface protein (SHBs). The viral DNA, a virus-encoded 
RNA-dependent DNA polymerase, a protein kinase activity which phosphorylates 
HBcAg and a genome-bound protein covalently linked to the 5，end of the long 
strand of HBV DNA are contained in a 27 nm nucleocapsid composed of 180 units 
of the hepatitis B vims core antigen (Figures 1 and 2). 
Aside from the above mentioned intact virus particle (Dane particle), 22 nm spherical 
and filamentous structures are also found in sera of infected patients. These mainly 
contain HBsAg but not viral DNA. 
1.2.2 Structure of the HBV Genome''''''' 
The HBV genome is small, with a size of only 3.2 kb containing 4 overlapping open 
reading frames (ORFs). It is a partially double-stranded circular molecule consisting 
of a long ‘minus，(L(-)) strand paired with a shorter ‘plus, (S(+)) strand of variable 
length. Although neither strand is closed circular by itself, the genome retains 
circular configuration through overlap of the 5' ends of the two strands (Figure 2). 
The origin of the long strand is at Direct Repeat 1 (DRl) whereas that of the short 
strand is at Direct Repeat 2 (DR2). The 3，end of the short strand, on the other hand, 
is at different nucleotide positions in different virus particles. 
A polypeptide serving as protein primer for L(-) strand replication is covalently 
bound to the 5' end of the L(-) strand while a 19 nt capped ribonucleotide is 
covalently attached to that of the S(+) strand, serving as primer for S(+) strand DNA 
synthesis. Attached to the 3，end of the S(+) strand, is a basic protein with HBV 
DNA polymerase and RNAse H activity. 
丨： 
[; The long strand contains all 4 ORFs: preSl/S2, preC/C, P, and X. Aside from these, 
the HBV genome also carries 4 promoters: SI promoter (SIP), S2 promoter (S2P), C 
i promoter (CP) and the X promoter (XP). In addition, it also has two enhancers, 
enhancer I (Enhl) and enhancer II (Enhll) and a glucocorticoid response element 
i , 
p (GRE), both concerned with regulation of gene expression, and a polyadenylation 
E. 
f signal used by all major transcripts residing within the pre-C region. 
j^；: 















Membrane bilayer ---~ 
Figure 1 
Schematic structure of the HBV particle. LHBs, large hepatitis B surface protein; 
MHBs, middle hepatitis B ?urface protein; SHBs, small hepatitis B surface protein; 
HBc, core protein; polymerase, virus-encoded RNA-dependent DNA polymerase ; 
DNA, 3.2 kb partially double stranded HBV DNA genome; genome bound protein, 
covalently linked protein; membrane bilayer, lipoprotein bilayer of cellular origin. 
(Adapted from ref. 43). 
/ / ^^^^^ \ 纖) 
。‘8 kb RNA 
‘ � 
Figure 2 
Genomic organization of HBV. The partially double stranded circle represents the 
viral genome, showing direct repeats 1 and 2 (DRl and DR2)，the SI, S2，X，and C 
promoters (SIP, S2P, XP, and CP, respectively), and the enhancers (Enhl and Enhll, 
respectively) as well as the glucocorticoid response element (GRE). The genome 
bound protein and the oligoribonucleotide are indicated at the 5，end of the L(-) strand 
and at the 5' end of the S(-) strand, respectively. The outer circle depicts the unspliced 
viral transcripts with their heterologous initiation sites and the common 
polyadenylation site. (Adapted from ref. 43). 
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27 
1.2.3 Funct iona l D o m a i n s of the HBV Genome — 
1.2.3.1 Enhancer I (Enhl) 
Enhl consists of a 5, basal enhancer module and a 3，accessory module and contains 
binding sites for various liver-specific and ubiquitous DNA-binding transcription 
factors. It activates transcription of genes from promoters including S2, C and X. 
L2.3.2 Enhancer II (Enhll) 
Enhll partially overlaps the C promoter and consists of 2 subunits: element A，which 
is responsible for liver specificity of Enhll through binding of liver-specific 
transcription factors, and element B，which is essential for ks function as 
transcriptional activator. 
1.2.3.3 preSHSHS 
Transcription starting from preSl yields preSl/preS2/S transcripts, which act as 
template for production of the large hepatitis B vims surface protein (LHBs). 
Because of liver specificity of the SI promoter, probably due to the presence of a 
binding site for hepatocyte nuclear factor 1, preSl-mRNA transcripts are only 
transcribed in hepatocytes. On the other hand, transcription of preS2/S, regulated by 
the S2 promoter, produces transcripts for the translation of middle and small hepatitis 
B vims surface protein (MHBs，SHBs). 
SHBs make up 90 % of the viral surface protein in patients' sera, while MHBs is 
speculated to function in viral adsorption to hepatocyte membrane through a highly 
conserved glycosylated amino acid in the preS2 region (asparagine-4). LHBs, on the 
other hand, accounts for only 1-5 % of all surface proteins. It has a vims-specific 
main determinant a comprising amino acids 2-13 of the preSl region as well as 
subtype-specific determinants d/y and w/r which are mutually exclusive, giving rise 
to the 4 major subtypes adw, ayw, adr and ayr. adw and ayw are the predominant 
subtypes in Europe, the United States of America and Africa; while adr is more 
frequent in South East Asia. Subtype ayr is the least common worldwide. 
Surface proteins mediate the adsorption of the virions to hepatocyte surface and are 
highly antigenic. Production of anti-HBs antibody after vaccination or infection 
provides immunity against wild type HBV infection. Mutations within the S region, 





Initiation of transcription within the preC region, which is regulated by the C 
promoter, yields C-mRNA for synthesis of HBcAg and viral polymerase，and reverse 
transcription during replication. On the other hand，initiation of transcription at a 
start codon upstream of the preC start codon is responsible for production of HBeAg， 
which is proteolytically processed before its secretion into semm. 
HBcAg is targeted by the host immune system for removal of hepatocytes supporting 
HBV replication. In fact, there is an inverse correlation between HBcAg expression 
and the severity of liver disease. Hence, mutations within the C gene may allow 
escape of HBV replicating hepatocytes from immune surveillance. 
HBeAg is associated with continued viral replication and high infectivity. Sero-
conversion from HBeAg to anti-HBe is associated with clearance of wt HBV and 
resolution of chronic liver disease. It is speculated that HBeAg is able to partially 
block immune response towards HBcAg and promote vims persistence due to its 
cross-reactivity with HBcAg on the T cell level. 
L2.3.5 Polymerase (P) Gene 
The P ORF encodes the hepatitis B viral polymerase (pol), a 832-amino acid protein 
with a calculated molecular mass of 93 kDa. However, the pol protein has not been 
detected in infected hepatocytes. Indirect evidence that the pol protein is synthesized 
in vivo comes from detection of anti-po/ antibodies in patients' sera. 
From studies conducted in bacterial and eukaryotic expression systems，we now 
know that pol is translated from pre-genomic C-mRNA and consists of an N-
terminus encoding a genome-bound protein linked to the 5, end of the L(-) strand, 
which serves as primer for reverse transcription, and a 3' C-terminus region with 
RNAse H activity. 
1.2.3.6 X Gene 
The X gene of the hepatitis B vims encodes the hepatitis B X antigen (HBxAg). 
HBxAg is detected in serum and liver of patients with HBV associated chronic liver 
disease. It is often the only vims antigen detected in such liver tissues, suggesting its 
importance in the pathogenesis of liver diseases. HBX has been reported to have 
trans-activating function. Genes trans-activated by HBX include viral and host genes 
such as ras, raf,''''''''''^ NF-hB,风!抖 C-MYC,''' TNF-A, and interleukin-6/^' Also, 
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HBX is capable of fully transforming non-tumorigenic cell lines. These, together 
with its ability to form complexes with wild type p53，strongly suggest a role for 
HBX in hepatocarcinogenesis. A more detailed account of HBX will be given in 
chapter 1.3. 
1.2.4 P a t h o g e n e s i s of HBV Infection'''' ' 
The pathogenesis of HBV infection varies greatly among different individuals. When 
HBV infection occurs at birth, more than 90 % of babies born to HBeAg + mothers 
become chronic carriers. In contrast, only 10 % of adults develop chronicity after 
acute infection, indicating the importance of a mature immune system in eradicating 
the vims after infection. Around 65 % of HBV infection in adults are sub-clinical and 
neither HBsAg nor virus is detected in blood. Twenty-five percent result in acute 
hepatitis and HBsAg is detectable in blood for 6 to 26 weeks, often accompanied by 
HBxAg and/or HBeAg. This is followed by clearance of the virus and its antigens 
from the blood and seroconversion to anti-HBs. Usually, this means resolution, but 
in some cases，patients who have sero-converted still carry the virus in their blood as 
detected by polymerase chain reaction (PCR). About 1 % of patients develop 
fulminant hepatitis following acute infection, which has quick onset and is often fatal. 
In 10 % of infected patients, HBsAg persists for more than 6 months and develop 
chronicity. These usually start with high levels of circulating virus, which then 
declines and becomes undetectable decades or years later. While 70 to 90 % of such 
patients are asymptomatic chronic carriers, others undergo 1 or more episodes of 
chronic reactivation of hepatitis representing efforts by the host immune system to 
eliminate the virus. Patients who finally eliminate the vims sero-convert to anti-HBX 
and anti-HBe, and finally resolve liver disease. However, there are also those who 
undergo the same serological changes but continue to replicate the vims and have 
episodes of serious liver disease. In either case，patients may develop cirrhosis, liver 
dysplasia and primary liver cancer. 
Primary liver cancer occurs most often in patients with HBsAg and progressive liver 
disease. In fact, HBV DNA is integrated in over 90 % of HBV-associated HCC. 
Although the site at which integration occurs in the human genome seems to be 
random, the region between DRI and DRII is the preferred viral site of 
recombination. To date, insertional inactivation of cellular genes by HBV DNA has 
I 
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only been observed in rare cases. Hence, it is believed that cis-inactivation of cellular 
genes is not the general mechanism of HBV-associated HCC in humans. However, 
integrated HBV DNA could still exert its effect on cellular gene expression by trans-
mechanisms. DNA tumor viruses such as adenoviruses, human papilloma viruses and 
the Epstein-Barr virus have been shown to cause malignant transformation through 
transcriptional transactivation. In HBV, HBx has been experimentally shown to have 
transactivating function, which is retained in the integrated state. The following 
chapter will discuss in detail the transactivation of cellular genes by HBX. 
1.3 HBx 
1.3.1 The HBV X Gene 
The HBx gene is conserved among all mammalian hepadnavimses but not found in 
the avian viruses. It was so-named because during its discovery, the deduced amino 
acid sequence did not correspond to any known proteins. It has an open reading 
frame of about 465 base pairs encoding a protein of 154 amino acids and a molecular 
weight of 17 kDa. A segment of 250 nt overlaps with the P gene at the 5，terminus 
and 25 nt with the precore region, while a segment of 190 nt does not overlap with 
other genes. The X region not only encodes the X protein but also contains 
functionally important elements such as the core promoter, enhancer II，direct repeat 
1 (DRl) and direct repeat 2 (DR2), which are implicated in the replication and 
expression of HBV DNA. Although shown to be able to transactivate viral and 
cellular genes, it does not exhibit DNA binding activity. 
Comparison of the amino acid sequence of HBX with that of ground squirrel 
hepatitis vims (GSHVx) and woodchuck hepatitis vims (WHVx) reveals 5 conserved 
cysteine residues: C' ' and Furthermore, HBX could be 
subdivided into 6 regions (A-F) with regions A，C，and E being more conserved than 
B and D. Region A, spanning aa 1-20，has 80 % identity and is the most conserved 
segment containing the conserved cysteines C^ and Region B (aa 21-57) is 
poorly conserved with only 5 % homology and is rich in hydrophobic amino acids. 
‘； 
Region C spans residues 58-84, shows 55 % homology and is characterized by 2 
conserved cysteines C^ ^ and C^^ Region D is located between aa 85-119 and shows 
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poor homology (17 %). Region E (aa 120-140) is well conserved (67 % homology) 
and contains 1 conserved cysteine residue C^ ^^  while region F (aa 141-154) is highly 
variable in length and shows no apparent h o m o l o g y ？。 
1.3.2 The HBX P r o t e i n 
HBX has been described as a promiscuous transactivator due to its ability to 
stimulate cis-elements of not only the HBV g e n o m e 严 b u t also that of other viral 
promoters such as simian vims 40 (SV40) early promoter/' ' ' ' ' ' ' herpes simplex virus-
tk promoter，34，35 long terminal repeats (LTR) of human immunodeficiency vims (HIV) 
types I and human T-lymphotrophic vims (HTLV) type I ? mouse mammary 
tumor vims (MMTV),''''' and Rous sarcoma vims (RSV).''''' HBX can also up-
OQ « . . 40 4142 1 
regulate expression of cellular genes such as c-myc, c-fos / c-]un, ’ ‘ cxi-
antitrypsin严 cx-fetoprotein，42 metallothionein,34 epidermal growth factor receptor,似 
RNA polymerase II and I I I , major histocompatibility complex I and II，*? 
intracellular adhesion molecule 1,8 (3-interferon,^^ interleukin 6 and 8尸7，49 tumor 
necrosis factor a'^^ and retinoblastoma.'' Since HBX does not bind to DNA, it is 
believed that transactivation of the above genes are mediated via protein-protein 
interactions. Cellular proteins reported to interact with HBX include serine 
protease cellular DNA repair protein,^^ and transcription factors such as ATF-
2严 CREB,54 Oct-1 产 RPB5 subunit of RNA polymerase'' TATA binding protein,'' 
TFIIB 128129 and TFIIH 严 
1.3.3 Preferent ia l HBX Expres s ion in Sera, Hepat i t i s , Cirrhos is 
and HCC 
HBX has been found to be present in the sera of hepatitis B vims infected patients as 
detected by ELISA. Western blot analysis has further identified 2 forms of the 
protein: pl7 (17 kDa) and pl3 (13 kDa).^ ^ pl7 is the more dominant of the two, with 
pl3 being variably present in a subset of sera also positive for pl7. It was observed 
that HBxAg may persist as the only HBV antigen present in the serum of HBV 
infected patients. Some patients who were transiently positive for HBsAg, HBeAg 
and HBV DNA in serum for less than 6 months were found to be persistently 
positive for HBxAg by both ELISA and Western blot, even years after disappearance 
of the other viral markers. 
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In a recent study by Su et al '' using 5 polyclonal and 6 monoclonal anti-HBX 
antibodies, HBX expression was found to be preferentially expressed in HCC and 
surrounding liver tissues as compared to HBsAg and HBcAg. It is expressed in the 
cytoplasm of 55.6 % (10/18) of HCCs and 53.3 % (16/30) of cirrhotic livers. In 
contrast, progressive reduction in expression of HBsAg and HBcAg was observed 
from parenchyma of HCC-free livers (HBsAg: 91.7 % (11/12); HBcAg: 50 % (6/12)) 
to non-tumorous tissue of HCC livers (HBsAg: 77.7% (14/18); HBcAg: 33.3 % 
(6/18)) to HCC (HBsAg: 27.8 % (5/18); HBcAg: 5.6 % (1/18)). Albeit with different 
percentages, similar results have been obtained by different groups. '^'^ ^ HBx DNA 
and RNA transcripts were also found more frequently than the preS2/S, C and S 
genes in HCC and adjacent liver tissue in both HBsAg positive and negative 
c a s e s . — 
The finding that HBxAg was preferentially expressed even in the absence of HBsAg 
and HBcAg suggests that HBX expression may occur in the absence of viral 
replication and is produced from integrated HBV DNA templates. Continued 
expression of HBxAg, however, does not seem essential for tumor persistence as 
HBxAg-negative tumors have been found even in patients positive for HBxAg in the 
surrounding non-tumorous tissues，。 
1.3.4 Cellular Localization of HBX 
Using immunohistochemical staining, cytoplasmic HBX expression was found in 
HCC and hepatitis tissue with or without c i r r h o s i s . O c c a s i o n a l reports of 
nuclear HBX expression in HCC and cirrhotic tissues'^ '^ ''^ ^ were found to be due to 
non-specific binding of the antibodies used, as pre-adsorption of the antibodies with 
recombinant HBX failed to eliminate the signal. This staining pattern was also 
observed in liver tissue sections without HBV infection.^ ® 
Aside from confirming cytoplasmic expression of HBX irrespective of cell cycle， 
transfection experiments have also demonstrated dense granular-structural expression 
pattern at the nuclear periphery. Using the Green Fluorescent Protein (GFP) 
reporter plasmid, co-localization of HBX with cytoplasmic proteasome complex, but 
not other cellular organelles, including plasma membrane, endoplasmic reticulum, 
Golgi body, lysosomes and mitochondria, has also been shown.^ '^^ ^ 
• I 
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1.3.5 Animal S tud ies 
Adenomas and HCCs were found to develop at a much higher frequency in HBx 
gene transgenic mice as compared to normal littermates/®'' Tumor formation 
seemed to require a certain threshold level of HBx expression, as another strain of 
HBx-transgenic mice with lower levels of HBx expression did not show increased 
HCC incidence as compared to control mice/^^''' Chronic hepatitis was also not an 
absolute pre-requisite. Tumor formation was preceded by altered foci formation, 
where DNA content analysis revealed the existence of aneuploid peaks and increased 
DNA synthesis.7i，72 
When HBx transgenics were cross bred with c-myc transgenic mice, the average 
tumor latency was found to be shortened by 2 to 3 months as compared to c-myc 
transgenics alone, reducing life span up to 25 Quantitative Northern Blot 
analysis also indicated a 4- to 5-fold increase in c-myc mRNA in bi-transgenics, 
suggesting a co-factor role for HBX in liver oncogenesis. 
1.3.6 Funct ional Studies on HBX 
1.3.6.1 Abrogation ofp53 functions 
The in-vitro binding of HBxAg and p53 has been demonstrated by several 
groups.i24’i25，i26，73 westeHi blot analysis of immunoprecipitates from liver homogenate 
of patients with HCC has also shown in-vivo binding of HBX and p53 in tumorous 
and non-tumorous tissue, strongly suggesting the existence of HBxAg-p53 
complexes in the livers of patients with Upon transfection with HBx, both 
exogenous and endogenous p53 were found to be sequestered in the cytoplasm of 
cells.127 It is suggested that the function of HBX in hepatocarcinogenesis is to cause 
the cytoplasmic retention of cellular p53. HBX-p53 complex formation may stabilize 
p53 and/or change its conformation and sequester it from the nucleus, inhibiting it 
from carrying out normal cellular functions. Also, the fact that p53 conformation is 
important for its functions and varies during the cell cycle may have important 
implications on regulation of the cell cycle,apoptosis^^'"^^ and transcriptional 
transacdvation.82 (to be discussed in the following chapters). 
Mutation analysis has identified the p53-binding site within HBX to reside in amino 
acids 102-136 at the C - t e r m i n u s ? On the other hand, two independent HBX binding 




portion (aa 101-314) and the oligomerization domain at the C-terminus (aa 315-393), 
with both parts probably contributing to HBX binding of full length Whether 
the N-terminal 100 amino acids of p53 participate in HBX binding is still unclear as 
conflicting results have been published. 
HBX has been documented to transactivate cellular regulatory sequences including 
c-myc, c-fos, AP-1, AP-2 AP-3，SP-1 and NFkB.'' In view of the binding between 
HBX and p53, it is tempting to assume that HBX mediates transactivation through 
p53 binding. However, transactivation activity of HBX was not found to require p53. 
In fact，transactivation activities of both HBX and p53 were found to be mutually 
inhibiting, indicating in-vivo functional interaction/^^'^^^'^' Binding of p53 to HBX 
was, however, not sufficient for inhibition of transactivation by HBX, indicating that 
the transactivation and p53-interacting regions of HBX are mutually interacting but 
distinct.126 It is now known that abrogation of p53 mediated transactivation by HBX 
is not by down-regulation of p53 expressions^ Whether or not this is through 
blocking of p53 binding to p53-responsive elements seems to differ depending on the 
element i n v o l v e d 严 M o r e o v e r , the effects of HBX on p53 binding with 
transcriptional factors also differs. p53 that was bound to HBX could still 
simultaneously bind TBP subunit of TFIID and p62 subunit of TFIIH尸 while HBX 
almost completely inhibited binding of p53 to ERCC3/' Since ERCC3 is involved in 
transcription-coupled repair, p53 may contribute to the maintenance of genomic 
integrity by modulating transcription and DNA nucleotide-excision repair 
processes.^' Blocking of p53 binding to ERCC3 by HBX could thus increase the 
mutation frequencies of important cellular genes leading to neoplastic transformation. 
1.3.6.2 Cell Cycle 
HBX has been shown to deregulate cell cycle control checkpoints and induce its 
progression.75，76 Transfection studies revealed that HBX accelerated the sequential 
activation of CDK2-cyclin E, CDK2-cyclin A complexes and CDC2-cyclin B in 
quiescent cells. HBX-expressing cells emerged from Gq/G^ arrest and entered S 
phase, in a Ras-dependent maimer, more quickly and to nearly twice the level as 
compared with untransfected The proportion of cells in the G2/M was also 
higher and appeared earlier/^ indicating HBX-accelerated transit through Go/Gj and 
G2/M checkpoints by activation of cyclin-dependent kinases. DNA synthesis was 
also increased in HBX-expressing cells, further showing mitogenic activity of HBX 
I 1 6 
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in-vitro,'' ' ' although a certain threshold level of HBX is required as transfected cells 
with low levels of HBX expression did not show increased mitogenic activity. 
1.3.6.3 Apoptosis 
Several lines of evidence support a pro-apoptotic function for HBX. Disruption of 
foci formation in NIH3T3 cells by HBx transfection''''' was reversed by the anti-
apoptotic protein Bcl-2, suggesting that disruption of focus formation was through 
apoptosis. Both DNA fragmentation and nuclear condensation were also observed in 
HBX expressing Chang liver c e l l s . In fact，the percentage of apoptotic cells showed 
a dose-dependent relationship with the amount of HBx plasmid transfected. In livers 
of HBX transgenic mice, low level HBX expression was not directly associated with 
apoptosis but rather sensitized hepatocytes to apoptotic stimuli.79 HBX has also been 
shown to enhance the apoptosis-inducing ability of agents such as staurosporine, 
cycloheximide and TNF-a in several cell lines.''''' This was shown to be HBX 
specific by restoration to normal levels through expression of antisense HBx 
mRNA.8i Among the different types of cell death, that induced by HBX was 
apoptosis-specific and was not found to be associated with mitotic cell death.^ ^ 
On the other hand, anti-apoptotic effects of HBx have also been documented. These 
include observations that co-injection of wt p53 and HBx plasmids into the nucleus 
of primary human fibroblasts abrogated apoptosis induced by wt p53 a l o n e ^ HBx 
expression in REV2 (rat fibroblast cell line) and Hep (hepatoma cell line) cells also 
rendered these cells resistant to growth factor depletion and exhibited a low apoptotic 
rate upon serum starvation. Even after prolonged serum starvation, these cells 
survived and re-entered S phase, undergoing DNA synthesis, which was not 
observable in HBx negative cells，supporting the notion of HBX being a strong 
mitogen. HBX-expressing Hep cells were also found to be resistant to TNF-mediated 
apoptosis.83 On the other hand, however, HBX has also been reported to sensitize 
cells to apoptotic killing by TNF-a.^ ® 
This anti-apoptotic activity of HBX was not associated with activation of cellular 
gene expression including those of pro- and anti-apoptotic genes such as bcl-2, bcl-
xL, bax and p53P A direct role played by HBX on apoptosis was recently found by 
the finding that HBX inhibited caspase 3 activity in transfected cells, although a 





proteolytic cleavage of caspase 3，which is necessary for the propagation of apoptosis. 
However, cleavage ofPARP, a major downstream substrate, was entirely blocked.'' 
p53-mduced apoptosis was reported to be involved with TFIIH-associated factors 
XPB and XPD. HBX was found to inhibit binding of p53 to XPB and XPD without 
binding to the 2 proteins by itself. Deletion constructs of p53 showed that a C_ 
terminal domain (CTD) within amino acid residues 293-393 was responsible for 
binding to XPB and XPD. This was also the region which interacts with HBX.'' It is 
likely that HBX prevents p53 binding of XPB and XPD by masking the p53 CTD. 
One explanation for the contradictory results regarding the function of HBX in 
apoptosis may be due to the different expression levels and mutations of p53 of the 
host. It is now believed that the pro- or anti-apoptotic function of HBX may differ 
according to the p53 status of the host, and does not necessarily require the activity 
of the suppressor protein. 
13.6.4 Proteasome Complex 
HBX has been found to co-localize with the proteasome complex in the cytoplasm of 
cells.67’84 Using a yeast two-hybrid system, HBX binding was found to be confined to 
a novel proteasome subunit, XAPC7, but not to other subunits including LMP-2, 
HC2, HC3，HC5 and HC8.'' Although the turnover rate of HBX is not affected by 
this association, proteasome dependent proteolytic cleavage of NF-KB p50 from its 
precursor pl05 was slowed down.^ ^ Furthermore, while co-transfection of XAPC7 
and HBx lead to an increase in transactivation activity, expression of antisense 
XAPC7 was found to inhibit transactivation by HBX.^ ^ These suggest HBX may 
alter cellular levels of transcription factors through modification of proteasome 
function, thus leading to changes in activation of transcriptional promoters and 
enhancers. 
1.3.6.5 DNA Damage and Repair 
The number of HBX-expressing Chang liver cells was found to decrease 
I significantly as compared to controls after UV-irradiation, indicating increased 
I susceptibility of HBX-expressing cells to the damaging effects of UV. 
i Furthermore, their ability to repair UV-damaged DNA was also decreased. This 
I degree of reduction was similar to those seen in xeroderma pigmentosum 
I complementation group E patients, suggesting that this level of interference is 
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biologically significant.86 These data suggest that HBX-expressing hepatocytes may 
be prone to genomic hypermutability leading to increased tumorigenicity. In fact, the 
affinity of HBX for UV-irradiated DNA was found to be significantly higher than 
undamaged DNA. This binding affinity was further increased in the presence of 
nuclear proteins, suggesting that DNA binding of HBX is mediated by nuclear 
factors， 
The human homologue of the monkey UV-damaged DNA-binding protein 
(UVDDB), XAP-1, is known to be involved in the repair of UV-damaged DNA. 
HBX was found to be able to bind XAP-1 in-vitro.^''^^ Mutational analyses have 
mapped the minimum binding domain for UVDDB in HBX to reside within amino 
acids 66-101.88 h b x mutant constructs that retain UVDDB binding were also found 
to inhibit DNA repair in transfected cells. However, some HBX mutants which were 
unable to bind UVDDB still retained capability to inhibit DNA repair，suggesting a 
close but not complete correlation between HBX-UVDDB binding and inhibition of 
DNA repair.86 also possible that the UVDDB binding region and the DNA 
repair-inhibiting region are closely related but distinct. HBX also inhibited p53_ 
dependent global DNA repair to a level similar to that of HBX-free, p53-null 
hepatocytes.89 Furthermore, modulation of gene expression by p53 is postulated to be 
through interaction with components of the basic transcriptional machinery, 
including TFIID and ERCC3. Although HBX did not directly bind ERCC3, it almost 
completely inhibited binding by p53. Since ERCC3 is involved in transcription-
coupled repair, p53 may contribute to the maintenance of genomic integrity by 
modulating transcription and DNA nucleotide-excision repair processes. Inactivation 
of p53 function by binding with HBX could thus increase mutation frequencies of 
important cellular genes leading to neoplastic transformation.^^ 
The liver of chronic HBV patients is characterized by cirrhosis sustained for many 
years. The risk of replication errors is likely to be increased. This process could be 
enhanced by compromised DNA repair caused by HBx expression, which could be 
rendered irreparable due to the sustained stimulus for proliferation，It is suggested 
that HBX may target the nucleotide excision repair (NER) complex via XAP-1, 
diminishing or even inhibiting cellular repair mechanisms, thus allowing the 
accumulation of mutations over time and finally leading to the development of 
hepatocellular carcinoma. 
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1.3.6.6 Signal Transduction 
Abrogation of HBX transactivation in a c-Jun and c-Fos null cell line was restored 
after co-transfection with functional c-Jun and c-Fos.^^ Moreover, DNA-binding of 
the transcriptional factor AP-1, a heterodimer of c-Jun and c-Fos，was also increased 
after transfection with HBx, showing that HBX transactivation occurs via AP-1 
activation，However, neither the direct binding between HBX and c-Jun (and thus 
AP-1) nor the transcriptional complex, has been found both in-vivo and in-vitro；' 
suggesting that HBX does not transactivate via direct interaction with transcriptional 
complexes but rather indirectly by stimulating regulatory pathways that in turn affect 
transcription factor activity. In fact, HBX induction of c-Jun activity was blocked by 
mutant forms of Ha-Ras and Raf-1, indicating involvement of a Ha-Ras- and Raf-1-
dependent signal transduction pathway in the activation of c-Jun transcriptional 
activity by H B x , 92 
Ras- and Raf- dependent signaling pathways are known to be involved in the 
induction of cell growth, proliferation and transformation. Ras is a member of a 
family of GTP-binding proteins, which carries out functions by initiating a cascade 
of threonine and serine phosphorylation events through Raf and mitogen-activated 
protein (MAP) kinases. While HBx expression stimulated the formation of active Raf 
and Ras-GTP complexes, dominant negative mutants of Ras and Raf fully blocked 
HBX induction of AP-l/DNA complexes? indicating the requirement of both 
proteins for induction of AP-1 DNA binding and that HBX functions upstream of 
Ras and Raf. HBx transfected cells were also found to contain a significant 
proportion of phosphorylated (activated) MAP kinase as compared to controls. 
Moreover, cells transfected with mutant Raf lacked significant MAP kinase 
activity,93 linking Ras, Raf and MAP kinase in a signaling pathway activated by 
HBX and suggests that MAP kinase is a downstream effector of HBX transactivation 
activities. HBX activates the Ras, Raf, MAP kinase cascade intracellularly and not 
through induction of secretion of autocrine factors as conditioned medium obtained 
from HBX-expressing cells failed to induce AP-1 DNA-binding activity and elevate 
Ras-GTP levels when used to culture HBx-negative cells， 
i 
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1.3.7 Var ia t ions in t h e H B x Gene 
13.7,1 In-vivo HBx Mutants 
Twenty mutational hot spots have been reported in the X protein located at aa 5，12， 
between 30 and 47，between 87 and 92, between 116 and 119，130 and 131.'' The 
most well characterized in-vivo HBx mutations are those found at nucleotides (nt) 
1762 and 1764 of the HBV genome. These include an A to T substitution at nt 1762， 
causing amino acid (aa) change from Lys to Met at codon 130 of the Z gene, and a G 
to A substitution at nt 1764, causing aa change from Val to lie at codon 131. 
86 % (19/22) of Z gene from HCC tissues were found to have these two mutations. 
These were only found in 85 % (17/20) of adjacent non-tumorous livers from the 
same patients with HCC, 8.3 % (2/24) of sera from chronic HBV patients without 
HCC，95 and 71.4 % (5/7) of DNA from fulminant hepatitis but not from acute 
hepatitis.96，97’98,99，ioo These mutations are located within the nuclear protein-binding 
DNA sequences of the core promoter and enhancer II and are speculated to have 
altered binding affinity for nuclear proteins, changing the transcriptional activity of 
HBV DNA.101 
In-vitro experiments have shown that mutations of nt 1762-1764 from AGG to TGA 
could no longer bind a liver enriched transcription factor and lead to 3-fold reduction 
in precore mRNA production and consequently HBeAg levels, probably as a result of 
reduced transcription factor binding. In contrast, vims production was found to 
increase as a result of the muta t ions . In fact, in-vivo data shows that the presence of 
a wild type AGG sequence at nt 1762-1764 is significantly associated with HBeAg 
positivity and anti-HBe negativity, while a non-AGG motif is associated with 
increased liver damage as reflected by elevated ALT levels .��� Also, the A to T 
mutation at nt 1762 was often found before or during HBe seroconversion and 
indicates immune activation and liver damage. While the wild type A-1762 was 
present in 86.8 % (33/38) of HBeAg-positive patients, this was only seen in 55.8 % 
(19/34) of patients after HBe seroconversion, indicating that chronic HBV infections 
start with wild type strain and that mutants emerge as a result of immune activation 
during HBe seroconversion， 
Aside from the above mentioned mutations, 8 nt deletions within codons 128-134 
have been reported in HCC, chronic, asymptomatic and silent hBV.川5，io6，io7，io8 
Transfection of a mutant HBx construct with an 8 bp deletion from nt 1760-1767 




production of HBsAg, HBcAg and HBeAg but either does not affect or even 
increases production of progeny virus in-vitro：'' It is suggested that reduced 
production of viral antigens might enable mutant viruses to escape immunodetection. 
1.3.7.2 Mutational Analysis of HBX 
Mutational analysis on HBX has revealed that the N-terminal aa 2-57 and C-terminal 
aa 141-154 could be deleted without affecting its transactivation ability."^'''''''' Thus, 
neither the N- nor C-termini of the HBX protein are required for transactivation. In 
fact, amino acids 2-30 appear to be involved in negative regulation of transactivation. 
Although the mechanism for this is still unknown, it is suggested that this may be 
through regulation of its own synthesis or by forming multimeric complexes, which 
are less efficient at transactivation than monomeric HBX/^^ 
Deletions and insertions within the region aa 58-140 were found to have deleterious 
effects on the transactivation activity of HBX, indicating that this segment is 
important for transactivation function. In fact, an HBx truncated mutant construct 
with only aa 58-140 displayed 60 % transactivation activity as compared to wild 
type.112 Combining results from several groups, it is now believed that the 
transactivation domain of HBX comprises 2 distinct regions: aa 58-84 and aa 110-
140.110111112 Amino acids 58-84 map to the region interacting with the RPB5 subunit 
of RNA polymerase while TATA-binding protein interacts with HBX via aa 110-
140.112 Neither of the regions alone were sufficient for transactivation activity, 
indicating that transactivation by HBX requires both regions.. Furthermore, while 
point mutation of conserved cysteine residue C did not affect transactivation activity 
of HBX, those affecting C^ ^ and C'^' resulted in dramatic loss of transactivation 
ability.n2 
Aside from transactivation function, amino acids 51-105 but not the N-terminal 50 
amino acids were found to be essential for inhibition of both apoptosis and caspase 3 
activity by HBX. Insertion of amino acids arginine-proline into position 68-69 
entirely inactivated the above func t ions^ Moreover, site directed mutations in aa 
136 and 139 eliminated both transactivation activity and binding with XAPC7, a 
proteasome subunit.^ ^ Mutations in the first domain did not affect XAPC7 binding 
but was found to be critical for transactivation function. These suggest that 




may play an important role in the function of HBX while the first domain may 
interact with other cellular factors important for transactivation function. 
A recent report has however, shown that HBX transactivation domains are neither 
required nor sufficient for cell transformation."^ REV2 cells are SV40 T-antigen-
positive tumor revertant cells, which are unable to grow in soft agar or form tumors 
in nude mice. Transfection with HBx caused these cells to display altered 
morphology, grow to a higher density and form large colonies in soft agar, 
demonstrating efficient re-transformation by HBX. The 2 transactivation domains of 
HBX were found to be inessential and insufficient for tumor promotion function. The 
N-terminal 50 amino acids of HBX, although showing no transactivation activity, 
was able to transform REV2 cells at the same efficiency as full-length HBX. On the 
丨 other hand, truncated HBX lacking the first 50 amino acids but retaining 
transactivation activity showed only very weak transformation capability. A 
: truncated HBX with amino acids 106-154 containing the putative p53 binding site 
did not exhibit transactivation activity and showed almost no transforming ability, 
while HBX with only aa 1-136 did not activate transcription but transformed 
I efficiently. These show that while HBX is an efficient tumor promoter as shown by 
, its ability to transform REV2 cells，the 2 known transactivation domains are 
I dispensable for transformation function. Transformation function is also restricted to 
S the N-terminal 50 amino acids of the protein, which is implicated in HBX 
I . 
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1.4 Objectives of this Study 
Chronic infection with the hepatitis B virus is one of the main etiologic factors of 
human hepatocellular carcinoma (HCC). In Hong Kong and Southern China, about 
10 % of the population are chronic carriers of the vims while 80 % of patients with 
HCC were found to be HBV carriers. Although HBV integrates its DNA into the host 
genome, cis-(iii)activation of cellular genes has only been reported rarely and no 
specific pattern has been observed. In recent years，the X gene of the hepatitis B vims 
has gained much attention due to its ability to transactivate both viral and cellular 
genes and its ability to interact with important cellular proteins such as p53, DNA 
repair proteins and transcription factors. HBx is thus speculated to play an important 
role in hepatocarcinogenesis of HBV associated HCC. 
However, the expression pattern of HBx in chronic hepatitis and HCC is still unclear. 
Both cytoplasmic and nuclear expression patterns of HBx have been reported. In 
addition, whether or not differential expression patterns of HBxAg may be related to 
mutations in the HBx has also not been addressed. 
This study, therefore, seeks to answer the following questions: 
1. Is HBx expressed in the cytoplasm or nucleus of tumorous and non-
tumorous liver tissues of patients with HCC? 
2. Are mutant forms of the HBx gene found in HCC tissues? And if so, 
3. Would HBx mutants have different expression pattern and/or function as 
compared to its wild type counterpart? 
To tackle these questions, formalin fixed, paraffin-embedded HCC tissues from Hong 
Kong and Xiamen, a city in Southern China, were obtained to study the expression 






； technique. The involvment of alterations in the HBx gene in the development of 
HCC was also studied by DNA sequencing. Cellular localization of HBx was further 
verified by transfection experiments using a Green Fluorescent Protein (GFP) 




Chapter 2 Methods and Materials 
2.1 Paraffin Embedding of Patient Tissue Samples 
2.1.1 Tissue Processing 
Formalin fixed tissues were trimmed to about 2 cm X 2 cm X 0.5 cm and placed in 
processing cassettes. These were then dehydrated 3 times with 75 % ethanol，once with 
80 % ethanol, twice with 95 % ethanol and twice with 100 % ethanol for 1 hour each. 
This was followed by immersing twice in Xylene, 1 hour each and twice in molten 
paraffin wax for 2 hours each. While immersed in last jar of molten paraffin wax，the 
tissues were subjected to vacuum at 0.6 mm Hg for another 1 hour to facilitate entry of 
paraffin wax into the tissues. 
2 人2 Paraffin Embedding of Tissue Samples 
Paraffin embedding was performed by transferring the tissues to the center of metal base 
moulds. A plastic embedding ring was then placed on top of the metal mould and molten 
paraffin wax was filled in. This was then placed on top of a cold plate for 1 hour to 
allow the paraffin wax to solidify, after which the metal base mould was removed. 
2.2 Sectioning of Paraffin Embedded Tissue Sections 
Paraffin embedded tissue blocks were mounted onto a rotary microtome. After setting 
the correct orientation, ten 4 x^m sections were sectioned from each tissue block and 
mounted onto APES-coated glass slides, dried on a slide dryer, and kept in slide boxes 
until further use. 
2.3 Immunohistochemical Staining of Paraffin Embedded Tissue Sections 
2.3 J Dewaxing of Paraffin Embedded Tissue Sections 
Formalin fixed, paraffin embedded tissue sections were first heated in the oven at 60 °C 
for 30 minutes and dewaxed in two jars of xylene (BDH Laboratory Supplies, Poole, UK) 
five minutes each. 





2.3.2 Rehydration of Tissue Sections 
The tissues were then rehydrated in graded alcohols as follows: absolute ethanol (BDH 
Laboratory Supplies, Poole, UK) twice, five minutes each; followed by 95 % ethanol 
twice, five minutes each，75 % ethanol once for five minutes and double distilled water 
for five minutes. 
2.3.3 Antigen Retrieval 
Antigen retrieval was then carried out by microwave boiling in 10 mM sodium citrate 
buffer, pH 6.0 for 10 minutes and cooling to room temperature. 
2.3.4 Quenching of Endogenous Hydrogen Peroxidase 
Endogenous hydrogen peroxidase was quenched by immersing the sections in a solution 
of 3 % hydrogen peroxide in methanol (both from BDH Laboratory Supplies, Poole, UK) 
for 20 minutes at room temperature in the dark. 
2.3.5 Blocking of Endogenous Biotin and Non-Specific Protein Binding 
After three 2 minute washings in PBS, pH 7.4，endogenous biotin was blocked by using 
an Avidin/Biotin Blocking Kit (Zymed, San Francisco，CA，USA) according to the 
manufacturer's instructions. Two drops of avidin solution were applied onto the tissues 
and incubated for 10 minutes at room temperature. The samples were then washed in 
PBS/0.05 % Tween 20, pH 7.4, three times for two minutes each and two drops of d-
biotin solution were applied. After 10 minutes incubation, the tissues were washed again 
in PBS/0.05 % Tween 20, pH 7.4，three times for two minutes each. Non-specific 
binding was blocked by goat non-immune serum provided in the H i s t o s t a i n ™ SP Kit 
(Zymed, San Francisco, CA, USA) for 30 minutes at room temperature. 
2.3.6 Antibody Incubation and Color Development 
Excess serum was then blotted off and the tissues were incubated with the appropriate 
antibodies for 1 hour at room temperature. The antibodies were then washed off by 
rinsing in PBS, pH 7.4 three times, two minutes each. Subsequent steps, including 





mixture incubation, were performed using Histostain™ SP Kit (Zymed，San Francisco, 
CA, USA) according to the manufacturer's instructions. Two drops of biotinylated 
secondary antibody were applied to the tissues and incubated at room temperature for 10 
minutes. After incubation, the tissues were rinsed in PBS/0.05 % Tween 20, pH 7.4，3 
times for 2 minutes each. Two drops of streptavidin horse-radish peroxidase conjugate 
were then applied onto the tissues and incubated at room temperature for 10 minutes and 
was rinsed in PBS/0.05 % Tween 20，pH 7.4，3 times for 2 minutes each after the 
incubation period. One drop each of substrate buffer, chromogen solution and 0.6 % 
hydrogen peroxide solution (all provided in the kit) was added to 1 ml of double distilled 
water and mixed. Two drops of this substrate/chromogen solution was then applied onto 
tissues and incubated for 8-10 minutes at room temperature and rinsed with double 
distilled water. 
23.7 Counterstaining and Coverslip Mounting 
The tissues were then counterstained with Mayer's Haematoxylin for 5 minutes and 
rinsed in tap water. This was then immersed in Scott's tap for 3 minutes to allow blue 
color development, rinsed in double distilled water, and covered with coverslip using 
GVA mounting solution (Zymed, San Francisco, CA, USA). 
Interpretation of Immunostaining Results 
Grading of the immunostaining results was performed by Mr. Charles M. L. Chan, 
Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong 
Kong, and confirmed by Dr. John Y. H. Chan, Department of Clinical Oncology, 
Faculty of Medicine, The Chinese University of Hong Kong, in a non-blinded fashion. 
Staining intensity was graded according to the following scale: -: negative; +: weakly 
positive; ++: moderately positive; +++: strongly positive. 
2.4 DNA Extraction from Frozen HCC Tissues 
2.4.1 Sectioning of Frozen HCC Specimens 
Frozen tissues were taken out from a -85 °C freezer, embedded with TissueTek " O.C.T. 
compound (Miles Inc., Elkhart，IN, USA) and fitted into a cryostat. Twenty 10 [im 
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sections were sectioned for each sample and placed in a clean 1.5 ml tube. A fresh 
cutting edge was used for each new sample to prevent cross-contamination of DNA. 
2.4.2 Proteinase KDigestion and Phenol!Chloroform Extraction 
Four hundred and fifty microliters of digestion buffer was added and incubated at 5 0 � C 
overnight. In the next day, 450 [xl of buffer-saturated phenol (GIBCO BRL Life 
Technologies, Gaithersberg，MD，USA) was added, the samples were gently mixed and 
centrifuged for 10 minutes at 1700x g at 4 °C. The top aqueous layer was transferred to 
a new，clean 1.5 ml tube and phenol extraction was repeated once more. After 
centrifugation, the top aqueous layer was transferred to a new, clean 1.5 ml tube and 
450 of a chloroform/isoamyl alcohol mixture (24:1) was added (both from BDH 
Laboratory Supplies, Poole, UK). This was mixed gently and centrifuged for 10 minutes 
at 1700X g at 4 � C , the top aqueous layer was then transferred to a new, clean 1.5 ml 
tube. 
2.4.3 Ethanol Precipitation and Re-suspension in Tris-EDTA (TE) Buffer 
The aqueous layer was then added with one-tenth volume of 2 M NaCl solution and two 
volumes of ice-cold absolute ethanol and placed in a - 2 0 � C freezer overnight. The tubes 
were then centrifuged for 30 minutes at 1700x g at 4 � C and the supernatant was 
discarded. The DNA pellet was washed with ice-cold 70 % ethanol by gentle inversion 
of the tubes several times, decanted and washed again with ice-cold absolute ethanol. 
The supernatant was also discarded and the pellet was air-dried for 30 minutes at room 
temperature. Finally, the DNA was resuspended in 200 fxl TE buffer pH 8.0 and kept 
at - 2 0 � C . Care was taken at all steps to prevent cross contamination among samples. 
2.5 Quantitation and Purity Check of Extracted DNA 
DNA concentration was quantitated using GeneQuant (Amersham Pharmacia Biotech 
UK Ltd., Buckinghamshire, UK) by taking absorbance readings at 260 nm, 280 nm，and 
330iim where double stranded DNA concentration (^ig/ml) equals to (A260-A330) X 50 X 
dilution factor. 
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Purity of the DNA was determined by the (A260-A330) / (八测-八��。）ratio in which a value 
ranging from 1.8 to 1.9 represents pure DNA. 
2.6 Quality Check for Extracted Genomic DNA 
2.6.1 Agarose Gel Electrophoresis 
A 1% agarose gel with 0.4 \ig/ml ethidium bromide in 0.5x TBE buffer was loaded with 
0.5 |Ag of extracted genomic DNA. Electrophoresis was done for 45 minutes at a 
constant voltage of 110 volts and the band pattern was visualized by using a UV 
transilluminator set at 320 nm. The appearance of high molecular weight DNA larger 
than 23 kb in all samples is representative of high quality genomic DNA. 
2(5.2 Polymerase Chain Reaction (PCR) of the P-glohin Gene 
Polymerase chain reaction of the housekeeping gene, the P-globin gene, was also done 
to test whether the extracted DNA was of quality suitable for PCR. A 20 reaction 
mixture consisting of Ix PCR buffer, 2 mM dNTP (Promega Corporation, Madison, WI, 
USA), 1.5 mM MgCl2, 2 i^M of each primer, 1 U Taq DNA polymerase (GIBCO BRL 
Life Technologies, Gaithersberg，MD，USA), 60 ng genomic DNA and Milli-Q water 
was prepared. An initial denaturation step of 2 minutes at 9 5 � C was first done, followed 
by 30 cycles of 1 minute 94 °C denaturation, 30 seconds 57 primer annealing, and 1 
minute 72 °C extension. A final extension time of 5 minutes at 72 °C was performed to 
ensure complete elongation of all PCR fragments. The appearance of a single, specific 
band after agarose gel electrophoresis in all samples imply that the quality of the 
extracted DNA is suitable for PCR. 
2.6J Analysis of PCR Fragments by Agarose Gel Electrophoresis 
A 2 % agarose gel was prepared by dissolving agarose (GIBCO BRL Life Technologies, 
Gaithersberg, MD, USA) in 0.5x TBE buffer added with 0.4 ^ig/ml of ethidium bromide. 
After setting, 10 \il of PCR product was added with 2 x^l of 6x loading buffer (Promega 
Corporation, Madison, WI, USA) and loaded into the gel. Electrophoresis was carried 
out under a constant voltage of 110 volts for 45 minutes and band patterns were then 
visualized under a UV transilluminator at 302 nm. 
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2.7 Polymerase Chain Reaction (PGR) Amplification of the S and X Genes of the 
Hepatitis B Virus 
A 20 [i\ reaction mixture consisting of Ix PGR buffer, 2 mM dNTP, 1.5 mM MgCl?，2 
HM of each primer, 1 U Taq DNA polymerase, 60 ng genomic DNA and Milli-Q water 
was prepared. An initial denaturation step of 2 minutes at 9 5 � C was first done，followed 
by 35 cycles of 1 minute 94 °C denaturation, 30 seconds 5 7 � C primer annealing, and 
1.5 minute 72 °C extension. A final extension time of 5 minutes at 72 °C was performed 
to ensure complete elongation of all PGR fragments. For primers HBxl226F and 
HBxl888R，the following modifications were done: AmpliTaq Gold™ DNA 
polymerase (Perkin-Elmer, Roche Molecular Systems Inc., Branchburg, NJ, USA) was 
used, MgCl2 concentration was 2.5 mM, a 10 minute initial denaturation step was done 
to activate the DNA polymerase, annealing temperature was 5 9 � C and 40 PGR cycles 
were done. 
2.8 Southern Blot ofHBx PGR Fragments 
2.8.1 Immobilization of DNA onto a Positively Charged Nylon Membrane and Pre-
hyhridization 
DNA was denatured by rinsing the gel with double distilled water and placing it in 
denaturation solution on a moving platform for 30 minutes at room temperature. The gel 
was then rinsed with double distilled water and neutralized by bathing in neutralization 
solution for 30 minutes on a moving platform at room temperature. A positively charged 
nylon membrane, Zeta-Probe (Bio-Rad Laboratories, Hercules, CA, USA), was used and 
a transfer pyramid was set up as shown in Appendix A2. After overnight transfer with 
lOx SSC, the membrane was rinsed with 2x SSC and UV crosslinked using Stratalinker® 
UV Crosslinker (Stratagene, La Jolla, CA, USA). The membrane was then placed inside 
a heat-sealable polyethylene bag and pre-hybridized with APH (Aqueous 






2.8.2 Radio-labeling of an HBV Probe 
An HBV whole genome probe was labeled using 100 ng of pAM-6 plasmid added with 
random primers solution (GIBCO BRL Life Technologies, Gaithersberg, MD, USA), 
denatured at 9 5 � C for 5 minutes and cooled on ice immediately. Five microliters of a 3 
dNTP mixture consisting of 2 mM each of dATP，dTTP and dGTP was added with 5 
of [a-^^P]-dCTP (10 mCi/ml). This, together with 40 U of Klenow fragment, was added 
to the denatured plasmid and incubated at 3 7 � C for 1 hour. The ' 'P labeled probe was 
then purified from unincorporated nucleotides by using QIAquick Nucleotide Removal 
Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. 
Five volumes of buffer PN (provided) was added to the reaction mixture and mixed. 
The reaction mixture was then added to a QIAquick spin column and centrifuged for 1 
minute at 6000 rpm in a bench-top centrifuge. The column was then placed in a clean 2 
ml collection tube and the used tube containing radioactive flow-through was discarded 
appropriately. The column was then washed by adding 500 buffer PE (provided) and 
centrifuged for 1 minute at 6000 rpm. This was discarded appropriately afterwards and 
washing was repeated with another 500 \il of buffer PE. The flow-through was discarded 
appropriately and the column was transferred to a new collection tube and centrifuged 
for an additional 1 minute at 13,000 rpm for complete removal of buffer PE. The column 
was then transferred to a clean 1.5 ml tube and labeled DNA was eluted by adding 50 \xl 
of Milli-Q water and centrifuged at 13,000 rpm for 2 minutes in a bench-top centrifuge. 
J Hybridization of a ^^P-labeled HBV Probe and Film Exposure 
The 32p-labeled probe was then denatured at 95 °C for 5 minutes and rapidly cooled in 
ice for 5 minutes. After replacing the APH solution inside the polyethylene bag with 
68 °C pre-warmed fresh APH solution, the denatured probe was quickly added into the 
bag and hybridized overnight at 68 °C. The membrane was then washed with 2x SSC 
solution pre-warmed to 65 °C twice, 15 minutes each, followed by washing with 0.2x 
SSC solution pre-warmed to 65 °C twice, 15 minutes each. The membrane was then 





inside a cassette with intensifying screen and exposed to a Kodak BioMax MS Film 
(Eastman Kodak Company, Rochester, NY, USA) for 2.5 hours at -85 °C. 
2.9 Cloning of PCR Fragments into pGEM®-T Vector for Sequencing 
2.9.1 Gel Extraction and Purification 
The band of interest was excised from an agarose gel using clean surgical blades, 
minimizing the size of the gel as much as possible and transferred to clean 1.5 ml tubes. 
DNA was then extracted from the gel by using QIAquick Gel Extraction Kit (Qiagen 
GmbH, Hilden, Germany) according to the manufacturer's instructions. Three volumes 
of buffer QXl (provided) was added to 1 volume of sliced gel (100 mg � 1 0 0 x^l) and 
incubated at 5 0 � C for 10 minutes. After the gel has dissolved completely, 1 gel volume 
of isopropanol was added to the sample and mixed. A QIAquick spin column was then 
placed in a provided 2 ml collection tube, loaded with the sample, and centrifuged for 1 
minute at 13,000 rpm in a bench-top centrifuge. The flow-through was discarded and the 
column was placed back in the same collection tube. Five hundred milliliters of buffer 
QXl (provided) was added into the column and centrifuged for 1 minute at 13,000 rpm 
to remove all traces of agarose. The column was washed by adding 750 \x\ of buffer PE 
(provided), letting stand in room temperature for 5 minutes, and centrifuged for 1 minute 
at 13,000 rpm in a bench-top centrifuge. The flow-through was discarded and the 
column was centrifuged for an additional 1 minute at 13,000 rpm to completely remove 
residual buffer PE. The column was then transferred to a clean 1.5 ml tube and the DNA 
was eluted by adding 50 of Milli-Q water and centrifuged for 1 minute at 13,000 rpm. 
2.9.2 Ligation 
Ligation was then carried out using pGEM®-T vector system II (Promega Corporation, 
Madison, WI, USA) by preparing a reaction mixture with 0.2 (ig of insert DNA, 0.2 \ig 
of pGEM®-T cloning vector, Ix ligase buffer, 50 ^M ATP, 0.3 U/pil of T4 DNA ligase 
and incubating overnight at 15 °C. 
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2.10 Transformation of competent DH5a cells 
2.10.1 Preparation of competent DH5 a using calcium chloride 
After 20 hours growth on LB agar plates at 37�C，a single DH5a colony was picked and 
inoculated into 100 ml of LB medium (GIBCO BRL Life Technologies, Gaithersberg, 
MD，USA) in a 1 liter conical flask and grown for 3 hours at 3 7 � C with 220 rpm 
shaking. Following transfer to sterile 50 ml tubes, the cells were cooled on ice for 10 
minutes and centrifuged at 4000 rpm for 10 minutes at 4 � C . The supernatant was 
discarded while the cells were resuspended in 10 ml of ice-cold CaCl? and stored on ice 
for 30 minutes. It was then centrifuged at 4000 rpm for 10 minutes at 4�C，discarding 
the supernatant and resuspending the cells in 2 ml of ice-cold CaCl? per tube. Aliquots of 
100 ul resuspended competent cells were frozen in - 8 5 � C until use. 
2.10.2 Heat Shock of Competent DH5a Cells 
One hundred microliters of frozen DH5a was quickly thawed by wanning in the hand 
and added with 10 x^l of plasmid DNA. Heat shock was then carried out by incubating 
the cells at 4 2 � C for exactly 90 seconds and cooled on ice for 2 minutes. Eight hundred 
and ninety microliters of LB medium (GIBCO BRL Life Technologies, Gaithersberg, 
MD, USA) was then added to each tube and incubated in a 37 °C water bath for 1 hour. 
2.10.3 Plating of Transformed Cells onto LB Agar Plates 
The cells were then centrifuged at 13,000 rpm for 30 seconds in a bench top centrifuge 
and 900 i^l of the supernatant was discarded. The remaining 100 LB medium was 
used to resuspend the cells and was completely plated on LB agar plates containing the 
appropriate antibiotic. For pGEM®-T cloning vectors, LB agar plates containing 50 
^g/ml Ampicillin and spread with 40 i^l of a stock solution of X-gal (20 mg/ml) and 4 fxl 
of IPTG (200 mg/ml) was used while LB agar plates with 50 pig/ml Kanamycin was 
used for pEGFP-Nl vectors (Clontech Laboratories Inc.,Palo Alto, CA, USA). 
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2.10.4 Screening of Transformants for Inserts 
Bacterial colonies were screened for the insert using blue/white selection. White 
colonies were produced by interruption of the P-galactosidase coding sequence due to 
successful cloning of the insert DNA and were thus picked for miniprep plasmid 
preparation. 
2.11 Miniprep of Plasmid DNA 
2.11.1 Inoculation of Bacterial Colonies 
Single bacterial colonies grown on LB agar plates were inoculated into 2 ml LB medium 
containing the appropriate selective antibiotic using sterile toothpicks and grown 
overnight at 37 °C with 220 rpm shaking. 
2.112 DNA Extraction by Alkaline Lysis and Phenol!Chloroform 
One and a half milliliter of the culture was then transferred to clean 1.5 ml tubes and 
centrifuged at 13,000 rpm for 30 seconds in a bench top centrifuge to pellet the cells. 
The bacterial pellet was then resuspended in 100 x^l of ice-cold Solution I by vigorous 
vortexing. Alkaline lysis was performed by adding 200 of freshly prepared Solution II， 
mixed gently by inversion several times，and placed on ice for 5 minutes. This was then 
neutralized with 100 \x\ of Solution III, mixed by inversion several times and placed on 
ice for another 5 minutes. The tubes were then centrifuged at 13,000 rpm for 10 minutes 
in a bench-top centrifuge and the supernatant was transferred to a clean 1.5 ml tube. 
Four hundred microliters of phenol/chloroform/isoamyl alcohol (25:24:1) was added, 
mixed by vortexing and centrifuged at 13,000 rpm for 5 minutes in a bench-top 
centrifuge. 
2.11.3 Ethanol Precipitation and Resuspension in TE Buffer 
The supernatant was transferred to a clean 1.5 ml tube mixed with 800 \xl of ice-cold 
absolute ethanol and precipitated at -20 °C for 30 minutes. The tube was then 
centrifuged at 13,000 rpm for 10 minutes in a bench-top centrifuge, discarding the 
supernatant afterwards. Finally, the plasmid pellet was washed with 800 ！ o f ice-cold 
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70 % ethanol, decanted, washed with 800 x^l of absolute ethanol, air dried and re-
suspended in 50 TE buffer. 
2.11.4 Confirmation of Positive Clones 
Clones positive for the ligated gene were confirmed by using both restriction digestion 
and PCR. Restriction digest was carried out as follows: A 20 d^ reaction mixture 
consisting of Ix buffer D (Promega Corporation, Madison, WI, USA), 9 fxl Milli-Q 
water, 5 U Ncol (Promega Corporation, Madison，WI, USA), 5 U Notl (Promega 
Corporation, Madison, WI, USA) and 30 ng HBx- pGEM®-T plasmid was incubated in a 
3 7 � C water bath for 2 hours. The resulting fragments were then analyzed by a 2 % 
agarose gel electrophoresis. PCR was done as described in Chapter 2.7. Clones were 
considered positive for the ligated gene only when both restriction digest and PCR gave 
positive results. 
2.12 Sequencing of pGEM®-T Cloned HBx PCR Fragments 
pGEM®-T clones with the HBx gene were diluted with Milli-Q water to the appropriate 
concentration (35 n g / � as suggested by the DNA Sequencing Facility of the Iowa State 
University, Iowa, USA, and sent to them for automated sequencing using ABI 377 
Automated DNA Sequencer (Perkin-Elmer，Roche Molecular Systems Inc., Branchburg, 
NJ，USA). Sequencing of both strands were done to minimize errors in reading at the 
extreme ends of both strands. 
2.13 Construction of the HBx-GFP plasmid 
2.13.1 PCR Amplification of HBx Gene Inserts 
Primers EcoRI-HBxATG and 5amHI-HBxl835 were used to PCR amplify HBx gene 
inserts starting from the start codon but without a stop codon for cloning into the 
pEGFP-Nl cloning vector. HBx-pGEM®-T plasmids of HKHCC 5 and 11 were chosen 
as samples for HBx gene with and without mutations at codons 130 and 131 respectively. 
A 20 reaction mixture consisting of Ix PCR buffer, 2 mM dNTP, 1.5 mM Mga^, 2 




Milli-Q water was prepared. An initial denaturation step of 1 minute at 9 5 � C was first 
done, followed by 30 cycles of 1 minute 9 4 � C denaturation, 30 seconds 5 7 � C primer 
annealing, and 1.5 minute 72 °C extension. A final extension time of 5 minutes at 7 2 � C 
was performed to ensure complete elongation of all PCR fragments. A 2 % agrose gel 
electrophoresis was done afterwards for analysis of the PCR products. 
2.13.2 Confirmation of HBx Insert Sequence by DNA Sequencing 
To confirm that the HBx inserts did not contain PCR-caused mutations, DNA 
sequencing was done to check its nucleotide sequence. HBx inserts produced from PCR 
were cloned into the pGEM®-T vector and sequenced as described in Chapter 2.12. 
2.13.3 Restriction Digest of HBx-pGEM®-T Plasmids to Obtain HBx Inserts 
After nucleotide sequence was confirmed, HBx inserts were cut out from the 
corresponding HBx-pGEM®-T clones by restriction digest with EcoRl and Sail. A 15 
reaction mixture consisting of Ix buffer D (Promega Corporation, Madison, WI, USA), 
2 x^l Milli-Q water, 0.75 U EcoRl, 0.75 U Sail and 50 ng HBx- pGEM®-T plasmid was 
incubated in a 37 °C water bath for 5 hours. The resulting fragments were then analyzed 
by agarose gel electrophoresis. 
2.13.4 Restriction Digest ofpEGFP-Nl Cloning Vector for Cloning 
The pEGFP-Nl cloning vector was cut open by restriction digest with EcoRl (Promega 
Corporation, Madison, WI, USA) and Sail (Promega Corporation, Madison, WI, USA). 
A 40 reaction mixture consisting of Ix buffer D (Promega Corporation, Madison, WI, 
USA), 29 Milli-Q water, 20 U EcoRl, 20 U Sail and 130 ng pEGFP-Nl cloning 
vector was incubated in a 37 °C water bath for 5 hours. The resulting fragments were 
then analyzed by agarose gel electrophoresis. 
2.13.5 Ligation of HBx Inserts into the pEGFP Cloning Vector 
A 20 i^l reaction mixture consisting of Ix ligation buffer (Promega Corporation, 
i Madison, WI, USA), 6 U T4 DNA ligase, 10 mM ATP, 80 ng HBx insert DNA, 90 ng 
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pEGFP-Nl cloning vector and 0.7 Milli-Q water was incubated at 1 5 � C overnight. 
Subsequent steps，including transformation of competent cells and screening for positive 
clones were done as described in Chapter 2.10. 
2.14 Large Scale Plasmid DNA Preparation 
Two hundred microliters of the bacterial culture from miniprep preparation was 
transferred to a 250 ml conical flask containing 100 ml LB medium with the appropriate 
selective antibiotic and grown overnight at 37 °C with 220 rpm shaking. Plasmid DNA 
from the culture was extracted by using Qiagen Plasmid Midi Kit (Qiagen GmbH, 
Hilden，Germany) according to the manufacturer's instructions. 
Bacterial cells were harvested by centrifugation at 6000X g for 15 minutes at 4 � C . The 
supernatant was discarded and the bacterial pellet completely resuspended with 4 ml of 
buffer PI (provided). Four milliliters of buffer P2 (provided) was added and mixed 
several times by gentle inversion and incubated at room temperature for exactly 5 
minutes. This was added with 4 ml of buffer P3 (provided) and mixed several times by 
gentle inversion and incubated on ice for 15 minutes. Centrifugation at 20，000x g for 30 
minutes at 4 °C was performed and supernatant containing plasmid was removed 
promptly. This was re-centrifuged at 20,000x g for 15 minutes at 4°C to remove 
suspended or particulate material. A QIAGEN-tip 100 column was equilibrated with 4 
ml of buffer QBT (provided) by allowing the column to empty by gravity flow. The 
supernatant was then added to the column, and allowed to enter the resin by gravity flow. 
The column was then washed with 10 ml of buffer QC (provided) twice and DNA was 
eluted with 5 ml of buffer QF (provided). DNA was precipitated by adding 3.5 ml of 
room temperature isopropanol to the eluted DNA, mixed and centrifuged immediately at 
15,000x g for 30 minutes at 4 °C. The DNA pellet was washed with 2 ml of room 
temperature 70 % ethanol and centrifuged at 15，000x g for 10 minutes. The supernatant 
was carefully decanted without disturbing the pellet. The pellet was then air-dried for 30 




2.15 Cell Culture 
HepG2 and HeLa cells were grown in D-MEM medium (GIBCO BRL Life 
Technologies, Gaithersberg, MD，USA) supplemented with 2 mM L-Glutamine and 10 
% fetal bovine serum in a humidified 37 °C incubator with 5 % CO?. The cells were 
harvested and subcultured after achieving confluence using a split ratio of 1:10. 
2.16 Transfection 
2.16.1 Seeding of Cells for Coverslip Growth 
Twenty-four well plates added with sterilized round coverslips were seeded with 1x10^ 
HeLa or 4x10^ HepG2 cells per well in 500 of D-MEM medium supplemented with 2 
mM L-Glutamine and 10 % fetal bovine serum (growth medium). Transfection was 
performed after allowing the cells to attach and adapt for 24 (HeLa) or 48 (HepG2) 
hours. 
2.16.2 Transfection using LipofectAMINE™ 
Transfection was done according to the manufacturer's suggested protocol. Solution A 
was prepared by adding 1 fxg of plasmid DNA with 100 |il of serum-free growth 
medium, while solution B was prepared by adding 7 LipofectAMINE" reagent 
(GIBCO BRL Life Technologies, Gaithersberg, MD, USA) with 100 \i\ of serum-free 
growth medium. The two solutions were then mixed together and incubated at room 
temperature for 45 minutes to allow DNA-liposome complexes to form. While waiting 
for the complex to form, cells were rinsed with serum-free growth medium once. 
After the incubation period, 800 \i\ of serum-free growth medium was added to the tube 
containing DNA-liposome complex and mixed. Two hundred and fifty microliters of the 
complex was gently added to each cell-containing well and transfection was allowed to 
proceed for 5 hours in a humidified 37 °C incubator with 5 % CO�. The transfection 
medium was then removed and replaced with complete growth medium. Cells were then 
fixed and visualized using fluorescence microscopy at the stated time in each experiment. 






2.17 Cell Fixation and DAPI Staining 
Coverslips grown with cells were taken out of 24-well plates and rinsed once with PBS. 
Cells were then fixed in a freshly prepared solution of 4% paraformaldehyde in PBS for 
10 minutes at room temperature. The cells were then washed in PBS, pH 7.4，3 times for 
5 minutes each and incubated in 0.5 fxg/ml DAPI solution for 10 minutes at room 
temperature in the dark. The cells were then washed in PBS, pH 7.4, twice for 5 minutes 
in the dark and mounted onto glass slides using GVA mounting solution (Zymed, San 




All chemicals were purchased from Sigma Chemical Company (Sigma, St. Louis, MO, 
USA) unless specified. 
2.19 Antibodies 
The Anti-99 antibody is a rabbit polyclonal antibody which recognizes the Hepatitis B 
vims X protein (HBX) and was given to us as a gift by Dr. Feitelson M. A.， 
Department of Pathology，Anatomy and Cell Biology, Thomas Jefferson University, 
USA. It was prepared using synthetic peptide spanning amino acids 100-114 of the 
HBX protein. 
2.20 Formalin-fixed, Paraffin Embedded Tissues of HCC Tissues from Xiamen 
Twenty-two paired tumorous, non-tumorous formalin-fixed, paraffin embedded HCC 
tissues were obtained from Professor N. S. Xia，Department of Biology, Faculty of 
Science, Xiamen University. Table 1 shows the histological diagnosis of the patients. 
2.21 Frozen Liver Tissues 
One abcess, one donor and thirteen paired tumor and adjacent non-tumorous frozen 
tissues were obtained from Dr. C. T. Liew, Department of Anatomical and Cellular 
Pathology, Faculty of Medicine, The Chinese University of Hong Kong. The tissues 
were around one to two cm in diameter and were stored in a -85 °C freezer until use. 
Histological diagnosis of the tissues was also made by Dr. Liew. Among the 13 paired 
samples, 10 were diagnosed as primary hepatocellular carcinoma, 2 metastatic 
adenocarcinoma and 1 metastatic adenoma. Formalin-fixed, paraffin embedded tissue 




Table 1. Data of Hong Kong and Xiamen patients recruited for this study 
Patient sample gex Age Diagnosis 
number 
Hong Kong cases (NT，T) 
F 6 1 C i r r h o s i s , HCC ~ 
M 49 Cirrhosis, HCC 
F 3 5 “ Metastatic adenocarcinoma, non-cirrhotic 
M 51 Cirrhosis, HCC 
9；^ M 55 HBV, Cirrhosis，HCC 
11,12 M ~ 6 5 ~ HBV, Cirrhosis, HCC 
1 3 ^ F 54 Metastatic adenocarcinoma, non-cirrhotic 
1 5 ^ M 46 _ Cirrhosis, HCC 
17,18 5 8 ~ HCC 
1 9 ^ M 7 1 M e t a s t a t i c adenocarcinoma 
F 29 Cirrhosis，HCC 
2 3 ^ M 69 HCC, non-cirrhotic 
25:26 ~ M 5 5 ~ HBV，HCC, cirrhosis 
F ~ Abscess 
28 F 2 4 Donor 
Xiamen cases 
1 I - I - I HCC . 
； 3 ~ - HCC 
4 “ ~ ： HCC 
； 5 = ： H C C 
7 - HCC — 
； 10 - HCC 一 
- ： HCC 
- ^ ： HCC 
16 M ~ W HCC 
‘ 21 M HCC 
. 24 4 4 ~ HCC 
！ 25 F "160~ HCC 
28 29 HCC 
29 ~ W 41 HCC 
‘ 30 M HCC 
！ 31 M ~32~ HCC 
34 M ~ 3 5 ~ HCC 
35 ^ HCC 
36 " l A T f HCC 
37 M 44 HCC “ 
38 M 58 HCC 
I — 
NT : non-tumorous tissue; T : tumorous tissue; HBV : hepatitis B virus carrier; HCC : hepatocellular 






staining use. Table 1 shows histological diagnosis of the patients. 
2.22 PCR reagents 
PCR buffer, magnesium chloride, dNTPs and Taq DNA polymerase, were all bought 
from GIBCO BRLLife Technologies, Gaithersberg, MD，USA. 
2.23 Primers 
The sequences of primers used for PCR are listed in Table 2. Primers (3-Globin, 
HBxl226F, HBxl888R, EcoRI-HBxATG, and 5flmHI-HBxl835, were purchased 
from GIBCO BRL Life Technologies, USA. Primers P5, P6, PIO，Pll, P12 and P14 
were kind gifts from Dr. Zhong Sheng, Department of Clinical Oncology, Faculty of 
Medicine, The Chinese University of Hong Kong. 
2.24 Plasmid 
The pAM6 plasmid contains the complete wild-type HBV DNA of subtype adw and is 
cloned into the BamHi site of the pBR325 cloning vector (GenBank accession no. 
L08855), kindly provided by Dr. Zhong Sheng, Department of Clinical Oncology, 
Faculty of Medicine, The Chinese University of Hong Kong. 
2.25 Enzymes 
Restriction enzymes EcoRI’ BamHl, Ncol, Notl and Taq DNA polymerase, were 
purchased from GIBCO BRL Life Technologies, USA. AmpliTaq Gold " Taq DNA 
polymerase was bought from Perkin-Elmer, Roche Molecular Systems, NJ, USA. 
2.26 Ligation Reagents 





































































































































































































































































































































































































































































Corporation, Madison, WI, USA. 
2.27 Cloning Vectors 
The pGEM®-T cloning vector (Appendix A3) used for cloning PCR fragments and 
subsequent sequencing, was purchased from Promega Corporation, Madison，WI, 
USA. It is a 3.0 kb cloning vector with single 3，-T overhangs at the insertion site which 
； base pairs with 3'-A overhangs introduced by Taq DNA polymerase during each 
t 
i elongation step in the PCR cycle. 
The pEGFP-Nl expression vector (Appendix A4), on the other hand, was purchased 
from CLONTECH Laboratories, Inc., Palo Alto, CA, USA. The vector contains a 
cloned green fluorescent protein (GFP) gene from the bioluminescent jellyfish 
j 
j Aequorea victoria, which yields a bright green fluorescence when expressed in 
. eukaryotic cells and excited at 488 nm, allowing visualization of the cloned gene of 
SI 
i interest using fluorescence microscopy. 
I 
！ 2.28 Competent Cell 
I . 
I Subcloning Efficiency DH5a Competent Cells was bought from GIBCO BRL Life 
tf, 
I 
Technologies, USA and was used in all plasmid transformation procedures. The 





i 2.29 HeLa and HepG2 Cell Line 
I 
^ The human hepatoblastoma cell line HepG2 was purchased from the American Type 
i 
I Culture Collection (ATCC). Its origin was from a 15 year old white male in Argentina 
I and does not have integrated HBV DNA sequences. 
I HeLa, also purchased from the ATCC, is a human cervix adenocarcinoma cell line, 
g： whose origin was from a 31 year old black female. 丨 4 5 
H 
Chapter 3 Results 
3.1 Hepatitis B Virus Carrier Status of HCC Patients from Hong Kong and Xiamen 
HBV carrier status of HCC patients from Hong Kong and Xiamen, China were 
determined by both immunohistochemical and molecular methods. A patient was 
considered an HBV carrier if at least one of the following was detected: 1.) presence of 
the hepatitis B virus s (HBs) and/or the hepatitis B vims x (HBx) gene (detailed below); 
or 2.) positivity of the HBx protein by immunohistochemical staining (also detailed 
below). 
According to the above criteria, 80 % (8/10) of our HCC cases from Hong Kong were 
found to be HBV carriers (Table 3). However, due to lack of patient data and difficulty 
of extracting DNA suitable for PGR use, we were unable to determine the HBV carrier 
status of HCC cases from Xiamen. 
3.2 Immunohistochemical Studies of the HBx Protein in Hong Kong and Xiamen 
HCC 
Immunohistochemical staining of the HBx protein using the rabbit polyclonal antibody 
anti-99 was performed to study its prevalence and localization in HBV associated HCC. 
Table 1 shows the histological diagnosis of HCC patient samples from Hong Kong and 
Xiamen. 
HBxAg was found to be strongly expressed in the cytoplasm of non-tumorous, cirrhotic 
tissues while low or undetectable expression was observed in the tumorous regions. 
(Figure 3). 
3.2.1 Cross Reaction of Anti-99 with Cytokeratin 18 (CK18) 
A recent article reported the cross reactivity of the anti-99 antibody with cytokeratin 18 
(CK18), which is highly expressed in cells surrounding the bile ducts? To distinguish 
between specific binding of anti-99 to HBx from its cross reaction with CK18，a 
monoclonal antibody against human CK18 was used to identify cells that stain positive 













































































































































































































































































































































































































































































































































































































































































































































































树 攀 都 ； 
龜 ； { v i i f ： 1 
i ： 娜 
1 } 
I 
！ Figure 3 
； ! 
� HBxAg staining in hepatocellular carcinoma and metastatic adenocarcinoma of the colon in 
the liver 
5 Above: differential HBX expression between non-tumorous (left) and tumorous (right) 
regions in primary hepatocellular carcinoma. (100 x magnification) 
, Below: weak background staining in metastatic adenocarcinoma of the colon in the liver. 
(100 X magnification) 
fc 
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Figure 4 
CK18 staining in non-tumorous tissue of a HCC patient 
Above: Intense staining is observed in cells comprising the bile ducts {yellow arrows). 
(100 X magnification) 
- Below: High powered view of CKl 8 staining in cells comprising the bile duct. 






comprising the bile ducts but not to hepatocytes of a non-tumorous tissue, while Figure 5 
shows only weak CK18 staining of tumorous tissue from the same patient. 
3.22 HBx Expression in HCC Patient Tissue Samples from Hong Kong 
While only weak background staining of HBx is observed in the liver tissue of a liver 
donor (Figure 6)，non-tumorous, cirrhotic tissues usually stained more intensely than its 
tumor counterpart as seen in Figure 3. In HCC with chronic HBV infection from Hong 
Kong, 71.4 % (5/7) of the cases stained positively for the HBx protein in non-tumorous 
regions while only 12.5 % (1/8) of tumorous tissue samples were HBxAg positive 
； (Table 3). HBxAg staining was mainly located in the cytoplasm of hepatocytes. Figure 7 
I 
I shows HBxAg staining in non-tumorous and tumorous tissue. Strong staining was also 
I found in cells comprising the bile ducts, which is apparently due to the cross reactivity 
i 
I ofanti-99 withCKlS. 
i 
3.23 HBxAg Staining in HCC Tissue Samples from Xiamen 
In HCC tissue samples from Xiamen，77.3 % (17/22) were HBx protein positive in non-
tumorous areas whereas only 18.2 % (4/22) of tumorous tissues were positively stained 
(Table 4). Again, HBx staining was located in the cytoplasm of hepatocytes. Both 
positivity rate and expression level of the HBx protein were also found to be higher in 
the non-tumorous than in the tumorous areas similar to those observed in HCC samples 
from Hong Kong. 
3.3 Agarose Gel Eectrophoresis of DNA Extracted from Frozen Liver Tissues 
To determine if the differential staining intensity of the HBx protein between tumor and 
non-tumorous tissues was due to alterations or mutations in the HBx gene, DNA was 
extracted from these samples. Liver tissues from 1 liver donor, 1 abscess, 3 liver 
I metastatic adenocarcinoma of the colon and 10 paired HCC tumorous and adjacent non-
tumorous frozen tissues from Hong Kong were extracted for DNA using the 
I phenol/chloroform method as detailed in Methods. Extracted DNA (0.5 \ig) was loaded 
into a 1 % agarose gel and electrophoresed at a constant voltage of 110 V for 45 minutes 
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Figure 6 
Weak background staining of donor liver tissue sample using the anti-99 anti-HBx antibody. 
Note that only cells comprising the bile ducts are intensely stained (yellow arrow). 






Differential expression of HBxAg between non-tumorous and tumorous tissue 
Above: Strong HBX expression in non-tumorous tissue (200 X magnification) 




Table 4. Summary of results for Xiamen HCC cases 
Patient . HBX Immunohistochemical Staining 
Sample No. Diagnosis (NT/T) 
I 一 HCC + + / - -
3 — HCC — + / -
4 — HCC 一 + / -
5 HCC — + / -
7 一 HCC + / - — 
10 HCC — ++/ + 
II — HCC — + / -
12 — HCC — - / -
13 — HCC — + / -
16 — HCC — + + / -
21 HCC — ++ / -
24 一 HCC - / -
25 一 HCC “ +++/ + 
28 一 HCC - + + / -
29 HCC 一 + / + 
30 一 HCC — - / -
31 一 HCC — + / -
34 HCC ++ / + 
35 — HCC — - / -
36 HCC — + / -
37 HCC — + / -
38 HCC - / - — 
Percentage* (%) 77.3 / 18.2 
HCC : Hepatocellular carcinoma; - : negative; + : weakly positive; ++ : moderately 
positive; +++ : strongly positive; 




than 23 kb which is representative of good quality DNA (Figure 8). However, DNA 
extracted from formalin-fixed, paraffin embedded HCC tissues from Xiamen failed to 
give DNA of sufficient quantity for further analysis. 
3.4 PCR Amplification of the fi-globin Gene 
To determine if the extracted DNA was suitable for PCR analysis, the P-globin gene was 
amplified using primers p-globinF and p-globinR (Table 2). All samples produced a 
band of the correct size (280 bp), indicating the suitability of the extracted DNA for use 
in PCR (Figure 9). 
3.5 PCR Amplification of the HBs Gene from Liver Samples of HCC Patients from 
Hong Kong 
To determine if our HCC patients were in fact hepatitis B vims carriers, the presence of 
the HBs gene was checked. The HBs gene was PCR amplified from DNA of liver tissue 
samples of HCC patients from Hong Kong using primers P5 and P6 flanking the HBs 
gene (Table 2). The result is shown in Figure 10. In HCC patients with chronic HBV 
infection, positivity for the HBs gene in the tumorous tissues was 87.5 % (7/8), which 
was slightly higher than the non-tumorous tissues (75.0 %, 6/8) (Table 4). 
3.6 PCR Amplification of the HBx Gene from Liver Samples of HCC Patients from 
Hong Kong 
To further analyze the structure of the HBx gene, PCR amplification of the HBx gene 
from tissue samples of HCC patients was performed using primer sets P l l , P12, 
HBxl226F and HBxl888R. Electrophoresis was carried out using a 2 % agarose gel 
afterwards and the resulting DNA bands were visually analyzed using a UV 
transilluminator set at 320 nm. Figure 11 shows the results when primers P l l and P12 
were used, while Figure 12 shows the results for primers HBxl226F and HBxl888R. 
Our data indicate that the HBx gene was detectable in 87.5 % (7/8) of the non-tumorous 
tissues while 37.5 % (3/8) the tumorous tissues of HCC patients with HBV infection 












I Figure 8 
I 
I Agarose gel electrophoresis of genomic DNA from various liver tissue samples from 
I Hong Kong. 
Lanes 1-26 : DNA from HCC tissue samples (corresponding to their respective patient 
sample number as in Table 1), lane 27 : DNA from an abscess tissue sample (patient sample 
27 in Table 1), lane 28 : DNA from a liver donor sample (patient sample 28 in Table 1), M: 




Detection of the P-Globin gene by PGR from various liver tissue DNA samples. 
Lanes 1-26: HCC tissue samples from Hong Kong (corresponding to their respective patient 
sample number as in Table 1), lane 27: abscess tissue sample (patient sample 27 in Table 1 
),lane 28: liver donor sample (patient sample 28 in Table 1), +: human placental DNA 
(positive control)，double distilled water (negative control)，M: X Hind III DNA marker 
p / ' . -'、'::、•"“二八：； 
Figure 10 
•i Detection of the HBs gene by PCR from HCC sample tissues 
y Lanes 1-26: HCC patient tissue samples from Hong Kong (corresponding to their respective 
patient sample number as in Table 1)，lane 27: abscess tissue sample (patient sample 27 in 
！j Table 1)，lane 28: liver donor tissue sample (patient sample 28 in Table 1), +: pAM-6 (wild 
type HBV whole genome plasmid, subtype adw) (positive control), -: human placental 
DNA (negative control), W: double distilled water, M: (^xl74 Hae III DNA marker. 
i 
1 
1 •MRIMISI【雄 M R l B T O M i l S i g l M ^ ^ B ^ H H ^ ^ ^ ^ w n ^ ^ ^ ^ ^ S I 
I 
Figure 11 
Detection of the HBx gene by PCR using primers P l l and P12. 
Lanes 1-26: HCC patient tissue samples from Hong Kong (corresponding to their respective 
patient sample number as in Table 1)，lane 27: abscess tissue sample (patient sample 27 in 
Table 1)，lane 28: liver donor tissue sample (patient sample 28 in Table 1)，+: pAM-6 (wild 
type HBV whole genome plasmid, subtype adw) (positive control), -: human placental 




Amplification of the HBx gene by PGR using primers HBxl226F and HBxl888R. 
Lanes 1-26: HCC patient tissue samples from Hong Kong (corresponding to their respective 
patient sample number as in Table 1), lane 27: abscess tissue sample (patinet sample 27 in 
Table 1), lane 28: liver donor tissue sample (patient sample 28 in Table 1)，+: pAM-6 (wild 
type HBV whole genome plasmid, subtype adw) (positive control), -: human placental 
DNA (negative control), W: double distilled water, M: (t)xl74 Hue III DNA marker. 
I 
3.7 Amplification of the HBx Gene from Serum Samples of Chronic Hepatitis B 
Virus Carriers from Hong Kong Using Nested PCR 
The HBx gene from the serum of chronic hepatitis B patients was also amplified by 
nested PCR using HBxl226F and HBxl888R as the first round outer primers, while 
HBxl579F and HBxl694R were the inner primers used for the second round of PCR. 
Figure 13 shows the result after the first and second round of PCR. The HBx gene was 
present in 79.1 % (19/24) of the serum of chronic hepatitis B vims carriers (Table 3). 
3.8 Southern Blot o f i f f lx PCR Fragments 
To confirm that the PCR products of primers HBxl226F and HBxl888R are truly of 
hepatitis B virus origin and not from human sequences, Southern blot analysis of the 
PCR products was performed. As seen in Figure 14, all PCR-amplified bands hybridized 
with a 32p-labeled HBV genome DNA probe, indicating that the PCR products generated 
using primers HBxl226F and HBxl888R were of HBV origin. 
3.9 Cloning and Sequencing of the HBx Gene in HCC and Chronic Hepatitis B 
Patient Samples from Hong Kong 
After confirming that the DNA bands in Figure 12 were truly of hepatitis B viral origin, 
, w e then cloned the HBx-PCR products derived from both serum and liver tissue samples 
into the pGEM®-T vector (Promega Corporation, Madison, WI, USA). These were then 
sequenced by automated sequencing using the ABI 377 Automated DNA Sequencer 
(Perkin-Elmer, Roche Molecular Systems Inc., Branchburg, NJ, USA). 
Figures 16 and 17 show the DNA sequence and the deduced amino acid sequence of 
HBx genes from our patient samples, respectively. A mutation was considered to have 
occurred if the nucleotide or the amino acid differs from that of pAM-6 or any of the 
wild-type sequences which were obtained from the GENBANK database at the same 
position. 
As shown in Figures 15 and 16，the most consistent mutations found are an A to T and a 
G to A base change in codons 130 and 131 of the HBx gene, leading to amino acid 
changes of lysine to methionine and valine to isoleucine, respectively (Figure 17). This 




IjHB ^ K m^^r- : i w^M 
Figure 13 
Above: Results of first round HBx PCR using primers PIO and P14. 
Below: Results of second round HBx PCR using primers HBxl226F and P12. 
Lanes 1-24: Serum sample of chronic HBVcarriers; + (above): pAM-6 (wild type HBV 
whole genome plasmid，subtype adw) (positive control); - (above): human placental DNA 
(negative control); + (below): Aliquot of PCR product from positive control of the first 
round PCR; - (below): Aliquot of PCR product from negative control of the first round 
PCR; M: (t)xl74 Hae III DNA marker. 
i 
1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 
‘ • 、•： 
m m 感 
2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 + — W 
Figure 14 
Southern Blot of HBx PGR products amplified using primers HBxl226F and HBxl888R 
(see figure 12) 
The pAM-6 plasmid (wild type HBV whole genome plasmid, subtype adw) was used as 
probe. Lanes 1-26: Hong Kong HCC patient tissue samples (corresponding to their 
resspective patient sample number as in Table 1)，lane 27: abscess tissue sample (patient 
sample 27 in Table 1), lane 28: liver donor tissue sample (patient sample 28 in Table 1), +: 
pAM-6 (wild type HBV whole genome plasmid, subtype adw) (positive control), -: human 
placental DNA (negative control), W: double distilled water. 
m 1 1 
善 
s r . . . , ..遍• ： ：•翻 
暴 
. M m m w-^w^^'MW-^^M • 惠 ： 赞 ) 绞 蠻 : 赞 : 楚 ： 蠻 • 
... _...暴 .暴 
： ： 森 ： 美 森 . . : • 急 . . 會 ： 森 譽 尊 • 眷 
^ Figure 15 
Eiectrophoregrams of the HBx gene DNA sequences from pAM-6 (wt HBx), HKHCC5， 
KHCCIO and HKHCCll showing wild type and mutated nucleotides in codons 127,130 
and 131. 
Blue arrows: A to G mutation in the first nucleotide of codon 127; Green arrows: T to C 
mutation in the second 职deotide of codon 127; Yellow arrows: A to T mutation in 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































B virus infection, 57.1 % (4/7) of non-tumorous liver tissue from HCC patients and 33.3 
% (1/3) of tumorous tissue from HCC patients (Table 5). Exceptions include one chronic 
hepatitis B virus carrier (HBVS21) which had a lysine to leucine change instead of 
methionine，and the non-tumorous tissue of one HCC patient (HKHCC9) only carried 
the codon 131 mutation. 
Aside from the above mentioned mutations, a T to C mutation in the second nucleotide 
of codon 127, leading to an amino acid change from isoleucine to threonine, was also 
quite common in our samples (Figure 16). This mutation was present in 41.7 % (5/12) of 
the HBV DNA from the serum of patients with chronic hepatitis B vims infection and in 
42.9 % (3/7) of non-tumorous tissue from HCC patients, but was absent from the 
tumorous tissue of HCC patients. Instead, an A to G mutation in the first nucleotide of 
the same codon occurred in 66.7 % (2/3) of the tumorous tissue of HCC cases, giving 
rise to an amino acid change from isoleucine to valine. This mutation was also found in 
8.3 % (1/12) of chronic carriers of the hepatitis B vims and 28.6 % (2/7) of the non-
tumorous tissue from HCC patients. Other mutations within the same region include a 
change from isoleucine to leucine (HBVS13) and another to aspartic acid (HBVS21). 
These results are summarized in Table 5. 
3.10 Expression Pattern of Wild-type HBX-GFP Fusion Protein in Transiently 
I 
I Transfected HeLa and HepG2 Cells 
丨 To investigate whether HBx gene with mutations in codons 130 and 131 would have 
！ different expression patterns as compared to the wild-type sequence, HBx gene with and 
I 
without the mutations were cloned into the pEGFP-Nl vector (GFP) (CLONTECH 
Laboratories Inc., Palo Alto, CA，USA), which contains the gene encoding the green 
J fluorescence protein (GFP), and transiently transfected into HeLa and HepG2 cell lines 
for expression studies. 
: Ligated HBx gene forms a fusion protein with GFP and emits green fluorescence which 
I can be examined by fluorescence microscopy. Figure 18 shows the expression time-
[ course of GFP (control) in HeLa cells at 6 and 60 hours post-transfection, while Figures 
19 and 20 show the changes in expression level and localization of the wild-type HBX 

































































































































































































































































































































































































































































































Expression of the green fluorescent protein (GFP) in HeLa cells at 6 hours post-transfection 
(above), and at 60 hours post-transfection (below). GFP expression is is consistently 








Differential expression patterns of the pAM-6 HBx-GFP with time in HeLa cells. 
Top : Diffused cytoplasmic expression pattern of HBxAg at 6 hours post-transfection. 
Middle: Punctate cytoplasmic/peri-nuclear expression pattern at 15 hours post-transfection. 
Bottom: 'Round-up' expression pattern overlapping with the nucleus at 60 hours post-
transfectioiL All figures are magnified 200 times. 
i 
BBimi 
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Figure 20 
Differential expression patterns of pAM-6 HBx-GFP with time in HepG2 cells. 
Top: Diffused cytoplasmic expression pattern at 9 hours post-transfection. 
Middle: Punctate cytoplasmic/peri-nuclear expression pattern at 15 hours post-transfection. 
Below: ‘Round-up’ expression pattern overlapping with the nucleus at 60 hours post-
transfection. All figures are magnified 200 times. 
i 
The expression of GFP in HeLa cells is consistently diffused throughout the cytoplasm 
and nucleus from 6 hours to 60 hours post-transfection (Figure 18). On the other hand， 
wild-type HBX-GFP fusion protein formed a diffused cytoplasmic pattern at 6 hours 
post-transfection (Figure 19 top panel) and then gradually accumulated to form peri-
nuclear punctate structures which were visible from 12 to 36 hours post-transfection 
(Figure 19 middle panel). These structures then finally progress into a ‘round-up， 
expression pattern overlapping with the nucleus, as seen from 48 to 72 hours post-
transfection (Figure 19 bottom panel). 
To determine if these phenomena were also present in cell lines of liver origin, the HBx-
GFP plasmid was also transfected into a hepatoblastoma cell line, HepG2. Although 
expression of the transfected HBx-GFP gene started 3 hours later in HepG2 cells (9 
hours post-transfection, Figure 20 top) as compared to HeLa cells (6 hours post-
transfection, Figure 19 top), expression levels and patterns of HBX-GFP were generally 
the same. Figure 20 shows the photos of the expression time-course of wild-type HBX-
GFP in HepG2 cells from 9 to 60 hours post-transfection. 
3.11 Expression Patterns of HBx-GFP with and without Mutations at Codons 130 
and 131 in HeLa Cell Line 
To determine if the commonly occurring mutations at codons 130 and 131 of the HBx 
gene would affect expression patterns, both mutant and wild-type HBx-GFP were also 
transiently transfected into HeLa cells. Figures 21 and 22 show the time-course of 
expression of HBx-GFP5 and HBx-GFPll in HeLa cells respectively. HBx-GFP5 was 
constructed by ligation of the HBx clone HKHCC5 (Figure 16), which does not carry 
mutations at codons 130 and 131，into the pEGFP-Nl expression vector while HBx-
GFPll was ligated with the HBx clone HKHCCll, carrying mutations at both codons 
130 and 131 (Figure 16). From the two series of Figures, it can be seen that both non-
mutated HBx-GFPS and the mutated HBx-GFPll displayed similar expression patterns 
as that of the wild-type HBx-GFP. All were expressed firstly in the cytoplasm as foci， 






Differential expression patterns of HKHCC5 HBx-GFP with time in HeLa cells. 
Top : Diffused cytoplasmic expression pattern at 6 hours post-transfection. 
Middle: Punctate cytoplasmic/peri-nuclear expression pattern at 15 hours post-transfection. 
Bottom: ^Round-up' expression pattern overlapping with the nucleus at 60 hours post-





Differential expression patterns of HKHCCl 1 HBx-GFP with time in HeLa cells. 
Top : Diffused cytoplasmic expression pattern at 6 hours post-transfection. 
Middle: Punctate cytoplasmic/peri-nuclear expression pattern at 15 hours post-transfection. 
Bottom: ‘Round-up’ pattern overlapping with the nucleus at 60 hours post-transfection. All 
figures are magnified 200 times. 
i 
3.12 Growth Kinetics of HeLa Cells Transfected with GFP and Wild-type HBx-
GFP with and without Mutations in Codons 130 and 131 
To further elucidate the function of the various HBx-GFP plasmids, their effects on the 
growth kinetics of transfected cells were analyzed. Figure 23 compares the growth 
curves of HeLa cells transfected with GFP alone, wild-type HBx-GFP, HBx-GFP5 and 
HBx-GFPll. The number of transfected cells was counted at different times post-
transfection. The percentage of cells transfected with GFP (control) emitting green 
fluorescence peaked at 42.5 %, while that of wild-type HBx-GFP, HBx-GFP5 and HBx-
GFPll were 51.4 %, 24.6 % and 18.1 % respectively at 50 hours post-transfection. 
From the results, it seems that while wild-type HBX-GFP was able to stimulate cell 
growth to some degree, mutant HBX-GFP (with and without mutations in codons 130 
and 131) inhibited cell growth and/or induced cell death instead. In this respect, HBx 
genes with and without mutations in codons 130 and 131 inhibited cell growth and/or 
induced cell death to similar degrees. 
81 
Time course of total expression of various 
X gene inserts in HeLa cells 
70 n = 
pAM-6 (wt) 
-m- HBx-GFPS (codon 130 and 131 wt) 
HBx-GFP11 (codon 130 and 131 m) 
GFP only 
6 0 -
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g " - XA r /,,.. V. 
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0 H 1 1 1 1 1 1 1 
0 10 20 30 40 50 60 70 80 
Hours after transfection (Hrs.) 
Figure 23 
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Chapter 4 Discussion 
4.1 HBxAg Expression in Tumorous and Surrounding Non-
tumorous Tissues 
This study was carried out to investigate: 1. the cellular localization and expression 
level of HBxAg in tumorous and cirrhotic, non-tumorous tissues of patients with 
HCC; 2. whether mutated forms of the HBx gene are involved in 
hepatocarcinogenesis; 3. if there is any correlation between HBxAg expression 
patterns and HBx gene integrity. Combining the results obtained from HCC samples 
from Hong Kong and Xiamen, HBx expression was observed in the cytoplasm of 
16.7 % (5/30) of tumorous tissues and 75.9 % (22/29) of adjacent cirrhotic, non-
tumorous tissues as determined by immunohistochemistry (Tables 3 and 4). Nuclear 
HBxAg expression was not observed in any of our patient samples, consistent with a 
recent report claiming that previous reports of nuclear HBxAg staining was due to 
cross-reactivity of the antibodies used.6o Our finding that HBx is mainly expressed in 
the cytoplasm of hepatocytes is in agreement with results from different reports.^ ®'^ '^^ ^ 
However, HBxAg was expressed more strongly and frequently in cirrhotic, non-
tumorous tissues than in tumorous tissues (Figures 3 and 7). Although this is in 
general agreement with other reports, the percentage of our HBxAg positive tumor 
cases is significantly lower than those reported by others. 6o，6i’62 The reason for this is 
unclear. However, it is not likely due to technical problems because of the following 
reasons: 1. The percentage of HBxAg positive cirrhotic, non-tumorous tissues is 
comparable to those reported by others.6o，6i 62 2. Only weak background staining was 
observed in a donor liver sample using anti-99 (Figure 6)，showing specificity of the 
HBxAg staining in our HCC patient tissue samples. 3. HBxAg negative tumors in 
patients with HCC have been reported, even in patients positive for HBxAg in the 
surrounding non-tumorous t i s s u e s . 吼 4 x^e anti-HBX antibody we used has been 
used extensively by other groups. Since X gene mutations have been reported to be 
present in both HCC tissues and adjacent non-tumorous tissues from China，we 
reasoned that the presence of mutated HBVZ gene(s) within the DNA of tumorous 
cells may lead to the production of mutated HBX proteins unrecognized by the anti-
! h e x antibody we used. This question is tackled in the next part of the project. 
i • 
丨i 
丨 8 3 
4.2 Detection of the HBx Gene in Sera, Non-tumorous and 
Tumorous tissues 
After showing that HBxAg is preferentially expressed in cirrhotic, non-tumorous 
tissues，and that tumorous regions have decreased expression, we questioned whether 
this was due to expression of mutated forms of HBxAg in tumorous areas. DNA was 
extracted from both tumorous and cirrhotic, non-tumorous frozen liver tissue samples 
of Hong Kong patients with HCC and the entire HBV Z gene was then sequenced. In 
addition, HBV X gene from the sera of HBV carriers without HCC was also 
sequenced as control. The entire HBV X gene was more often found in the 
surrounding cirrhotic tissues (87.5 %) than in the tumorous areas (37.5 %) (Table 3)， 
while it was present in 50.0 % (12/24) of sera from chronic HBV patients without 
HCC. Caution should be taken in interpreting this data. While PCR amplified HBx 
genes from liver tissues are mostly amplified from integrated sequences, those 
obtained from sera are from replicative viral particles from the serum of patients and 
has not been integrated into the host genome. The possibility that x gene negativity in 
some of the samples was due to degradation of extracted DNA was excluded since 
all of the genomic DNA extracted from liver tissue samples were larger than 23 kb, 
which are representative of good quality DNA (Figure 8). Suitability of the extracted 
DNA for the polymerase chain reaction (PCR) was also checked by PCR 
amplification of a region of the housekeeping gene, the /3-globin gene, which gave 
positive results for all DNA samples (Figure 9). Our results also show that the entire 
hepatitis B virus x gene is more often found in cirrhotic, non-tumorous areas than in 
tumorous counterparts. This is consistent with the possibility that after HBV genome 
integration and years of cirrhosis, a subset of cells with growth advantage and 
decreased DNA repair ability multiply through clonal expansion and initiate 
tumorigenesis. In fact, the HBX protein has been found to deregulate cell cycle 
checkpoints leading to cell cycle progression'' ' ' and compromise cellular DNA 
repair capability.8i’85-m Since the priming site near the 3，end of the primers used in 
PCR is critical for successful amplification of the gene of interest, tumorous cells 
with defective DNA repair mechanisms may contain mutated copies of the HBV 
genome, leading to decreased positivity rate of the intact x gene in tumorous tissues. 
I Moreover, the less frequent detection of the intact x gene and HBxAg expression in 
tumorous tissues as compared to surrounding cirrhotic tissues suggest that the intact 
84 
HBX protein may not be necessary for maintenance of the tumor but rather have a 
more important role in the early stages of tumorigenesis. This later argument is 
supported by the fact that among our tumor tissue samples, there are some which are 
positive for the intact HBx gene but negative for the HBX protein, indicating that 
expression of the HBX protein is not a necessity for tumor maintenance. 
Since we have now obtained HBx gene sequences from the sera of patients with 
chronic hepatitis B, the cirrhotic, non-tumorous liver tissues of patients with HCC 
and tumorous liver tissues of patients with HCC, the next part of the project was to 
sequence the amplified HBx gene to see whether any of these sequences are mutated 
and if so, how often and at which regions. 
4.3 HBx Gene Mutations in Chronic Hepatitis and HCC 
After cloning the HBx gene obtained from the sera of patients with chronic hepatitis 
B，the cirrhotic, non-tumorous tissues of patients with HCC and their tumorous 
counterparts, sequencing of the HBx gene was performed, which revealed numerous 
mutations within the x gene. Figures 16 and 17 show the nucleotide and deduced 
amino acid sequences of the HBV x gene obtained from our patient samples 
respectively. The criterion for consideration of nucleotides and amino acids to be 
mutated is described in Chapter 3.9 of this thesis. Sporadic nucleotide mutations 
leading to amino acid changes occur over the entire length of the x gene as seen in 
Figures 16 and 17. The regions at which these mutations occur generally match with 
reported mutational hotspots within the HBx gene 29 with a few differences which 
may be attributed to variations of the HBV strains. 
4.3.1 Codon 127 (HBV nt 1752-1754) 
The most consistent mutations found in our patient samples include mutations in 
codons 127，130 and 131. Codon 127 (HBV nt 1752-1754) has not been reported to 
be one of the several mutational hotspots in HBx However, among our patient 
samples, it was mutated in 50 % (6/12) of the sera of patients with chronic hepatitis 
B, 71.4 % (5/7) of the non-tumorous tissues from HCC patients and 66.7 % (2/3) of 
the tumorous tissues from patients with HCC (Table 5). Although its functional 
significance is still unclear, Kidd-Ljunggren et al''' have reported that the presence 
of at least one point mutation within nt 1751-1755 (spanning codons 126-128 of the x 
gene) was significantly associated with liver damage as determined by elevated ALT 
85 
i 
levels. Moreover, according to a recently proposed model for the folding of pre-
genomic RNA/^^ with the exception of an A to G mutation at nt 1752, all mutations 
within nt 1751-1755 of the HBV genome were predicted to be stem-disrupting and 
would lead to enhanced viral replication. 
In our patient samples, two different codon 127 mutations were found: an A to G 
mutation in the first nucleotide (nt 1752) leading to an amino acid change from 
isoleucine to valine and a T to C base change in the second nucleotide (nt 1753) 
leading to an amino acid change from isoleucine to threonine. The G他 mutation 
(non-stem disrupting) was most frequently found in the tumorous tissues from 
patients with HCC (66.7 %, 2/3), followed by the cirrhotic, non-tumorous tissues 
from patients with HCC (28.6 %, 2/7) and least in the sera of chronic hepatitis 
patients (8.3 1/12). On the other hand, the mutation (stem disrupting) was 
only found in the sera of chronic hepatitis patients (41.7 5/12) and in the cirrhotic, 
non-tumorous tissues of patients with HCC (42.9 3/7) and was totally absent from 
the tumorous tissues of patients with HCC (0.0 %, 0/3)' (Table 5). Although the 
frequency of mutation from isoleucine to valine shows an increasing trend from 
chronic hepatitis patients to cirrhotic, non-tumorous tissues of patients with HCC to 
tumorous tissues of the same patients; while an amino acid change from isoleucine to 
threonine shows a decreasing trend, it is difficult to determine whether this is in any 
way associated with the development of HCC because of our limited number of x 
gene positive samples and the lack of data from the literature. 
4.3.2 Codons 130 and 131 (HBVnt 1761-1766) 
HBx gene amplified from the tumorous tissues of patients with HCC harbored 
mutations in codons 130 (ntl762, AAG to ATG) and 131 (nt 1764，GTC to ATC) in 
33.3 % (1/3) of cases. This double mutation was also found in 57.1 % (4/7) of the 
cirrhotic, non-tumorous areas of the same patients with HCC and in 66.6 % (8/12) of 
sera from chronic hepatitis patients without HCC (Table 5). Comparing our results 
with those published by Hsia et al严 the same mutations were found in 86.4 % (19/22) 
of HCC tissues, 85.0 % (17/20) of adjacent non-tumorous tissues from the same 
patients with HCC and in only 8.3 % (2/24) of sera from patients with chronic 
hepatitis B without HCC. The apparent differences between our results may be 
attributed to one or more of the following reasons: Firstly, different geographical 
sources of patient samples: ours were from Hong Kong, theirs were from Qidong and 
86 
Beijing. Etiological differences such as aflatoxin contamination of food and 
variations in the HBV strain among the three regions might lead to different results. 
One example is that a G to A mutation at nt 1896，which is believed to be related to 
the development of fulminant hepatitis, is rarely found in cases from France^^^ and 
the United Statesi” but is quite common in cases from I s r a e l , s o u t h e r n 
Mediterranean countries^^^ and Japan.120 Secondly, our limited sample size may have 
underestimated the real occurrence of this double mutation in the tumorous and non-
tumorous tissues of patients with HCC. 
During the stage of HBV infection at which HCC develops, HBV DNA is commonly 
integrated into the host's chromosomal genome in infected liver cells. Since 
numerous hepatocytes are infected, single round PGR should be enough to amplify 
copies of HBx gene within hepatocytes. The chance of getting false negative results 
is further decreased by our use of 2 different sets of primers to amplify the HBx gene 
within hepatocytes. Therefore, from our results, the presence of mutations in codons 
130 and 131 of the HBx gene in Hong Kong is most frequent in the sera of patients 
with chronic hepatitis B，followed by the cirrhotic, non-tumorous tissues of patients 
with HCC and lastly, the tumorous tissues of patients with HCC. Increasing the 
number of HBx gene positive patient samples in future sequencing studies will 
further confirm the validity of this finding. 
In contrast to the results of Hsia et al, our results support the view that this double 
mutation is commonly found in the sera of patients with chronic hepatitis B. This is 
also supported by the results published by several different groups^ '^^ ^^ '^ ^^  In fact, 
transfection studies have shown that HBV genome introduced with the and 
mutations produce 2- to 3-fold more virions than the wild-type due to increased 
replication e f f i c i e n c y T h i s provides support and an explanation for the 
predominance of this quasispecies in the serum of patients with chronic hepatitis. 
43.3 Lack of Correlation Between HBx Gene Mutations and Lack of HBxAg 
Expression 
No correlation could be found between HBx gene mutants and their lack of 
expression in tumorous tissues in our patient samples. Failure to detect HBxAg in 
such tissues may have been due to HBxAg being not expressed in such cases or that 
expression was below the detection level of the method used. Whether HBx is 
87 
transcribed or not in those samples could be confirmed by mRNA in-situ 
hybridization, RT-PCR, or Northern Blot in future studies. 
4.4 Cellular Localization of HBxAg in Transiently Transfected 
Cell Lines 
To investigate whether naturally occurring HBX protein mutants with mutations in 
codons 130 and 131 have different cellular localization as compared to the wild-type, 
HBx gene with and without mutations in codons 130 and 131 were cloned into the 
pEGFP-Nl expression vector (CLONTECH Laboratories Inc., Palo Alto, CA, USA), 
which carries a reporter gene encoding the Green Fluorescent Protein (GFP), and 
transfected into HeLa and HepG2 cell lines to study their cellular expression patterns 
with time. 
Figures 21 and 22 show that HBxAg-GFP with and without mutations in codons 130 
and 131 have apparently similar expression patterns. While the expression of the 
GFP protein is consistently diffused throughout the cytoplasm from 6 to 60 hours 
post-transfection (Figure 18)，the expression pattern of the HBX-GFP protein with 
and without mutations in codons 130 and 131 is mainly diffused and cytoplasmic at 6 
hours post-transfection. At 15 hours post-transfection, this develops to a punctate 
cytoplasmic/peri-nuclear expression pattern and finally, at 60 hours post-transfection, 
a 'round-up' expression pattern overlapping with the nucleus is seen. This change in 
expression pattern with time is also consistently seen in both HeLa and HepG2 cells 
transfected with the wild-type HBX -GFP protein, as seen in Figures 19 and 20. 
Our results match those published by Sirma et al who, also by using the GFP 
reporter gene，showed that the cytosol is the prime localization of HBxAg 
irrespective of the cell cycle, with a fraction of HBxAg being associated with the 
nuclear membrane. HBX-GFP was expressed as discrete granular foci and was 
distributed throughout the cytoplasm. They did not see any significant changes in this 
distribution pattern during the cell cycle and HBxAg was not found to translocate to 
the nucleus. Using confocal laser microscopy, they have been able to detect a 
fraction of the expressed HBX-GFP to be associated to the nuclear membrane. 
Furthermore, they have found that HBX-GFP was co-localized with cytosolic 
proteasomes. Although this did not affect the turnover rate of HBX-GFP, it was 
found to slow down the proteolytic generation of N F - K B p50 from its precursor pl05. 
88 
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This shows that HBxAg expression modifies a proteasome-dependent biological 
activity and substantiates the functional significance of this co-localization. 
Although Siraia et al 们 did not find the cellular localization of HBX-GFP to change 
during the cell cycle, we found that the expression pattern of HBX-GFP actually 
changes with time passed after transfection i.e. from a diffused cytoplasmic pattern 
to a granular cytoplasmic/peri-nuclear pattern and finally to a ‘round-up，pattern 
overlapping with the nucleus (Figures 19-22). 
4.5 Functional difference between wild-type and mutant HBX 
protein 
After showing that the cytoplasm and, to a lesser extent, the peri-nuclear region, are 
the prime localization of the HBX protein, which then gradually accumulates and 
overlaps with the nucleus, our next approach was to investigate whether wild-type 
and mutant forms of the HBX protein are functionally different in transfected cells. 
As seen in Figure 23, while the percentage of HeLa cells expressing the GFP protein 
peaked at 42.5 % 50 hours after transfection, 51.4 % of the HeLa cells were found to 
express the wild-type HBX protein after the same period of time. Comparison of the 
percentage of cells expressing HBX-GFP5 (with wild-type aa 130 and 131) and 
HBX-GFPll (with mutant aa 130 and 131) does not show much difference. 
Interestingly, the percentage of HeLa cells expressing either one of the 2 mutant 
HBX-GFP protein was much lower when compared with cells expressing the wild-
type form, only reaching 24.6 % (HBx-GFP5) and 18.1 % (HBx-GFPll)， 
respectively. This suggests that naturally occurring mutant forms of the HBx gene 
function differently as compared with that of the wild-type. Our data supports the 
view that mutant forms of the HBX protein are much more efficient in inducing cell 
death than wild-type HBX. The significance of this is currently unknown. However, 
it is possible that after infection with wild-type HBV, expression of the wild-type 
HBX protein provides a stimulus for continual liver cell growth so that virus 
replication is maintained. Gradually, mutant forms of the HBV emerge through 
natural selection. The subsequent expression of mutant forms of the HBX protein 
I stimulate liver cell death and provides the liver with a stimulus for regeneration, thus 
i maintaining a suitable environment for HBV replication. After years of viral 
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Chapter 5 Conclusions and Directions for 
Further Studies 
5.1 Conclusions 
1. The expression of HBxAg is much higher and more often found in cirrhotic, non-
tumorous tissues (75.9 %) than in HCC tissues (16.7 %). This was not found to be 
due to mutations. It is possible that the expression of the HBX protein is not 
required for tumor maintenance but rather plays a more important role during 
chronic carriage and/or the early stages of tumorigenesis. 
2. The HBx gene was more commonly found in the surrounding non-tumorous 
tissues (87.5 %) than in the tumorous tissues (37.5 %). HBx gene with mutated 
codons 130 and 131 was found in 57.1 % and 33.3 % of the non-tumorous liver 
tissues from HCC patients and the tumorous liver tissue of HCC patients 
respectively. In contrast to previous reports, mutations in codons 130 and 131 of 
the HBx gene were also commonly found in the sera of chronic hepatitis B 
patients, suggesting that such mutants may be important during the chronic stage 
of liver disease or the early stages of hepatocarcinogenesis. On the other hand, 
another commonly found mutation in our patient samples, codon 127 mutation, 
was present in 50 % of the sera of patients with chronic hepatitis, 71.4 % of the 
non-tumorous liver tissues of HCC patients and in 66.7 % of the tumorous liver 
tissues of HCC patients. 
3. Our results show that HBxAg is mainly expressed in the cytoplasmic / peri-nuclear 
region. As time passes by, HBX gradually migrates to nucleus, giving an 
expression pattern overlapping with the nucleus. This type of expression pattern is 
the same for both wild-type and mutant HBX-GFP. 
4. While wild-type HBX-GFP seems to be able to induce cell growth / proliferation, 
mutant HBX-GFP was apparently able to inhibit cell growth and/or induce cell 
death. Such functional difference between the wild-type and mutant HBX protein 
may have important implications in hepatocellular carcinoma. 
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5.2 Directions for Further Studies 
1. We have found low or undetectable expression of HBxAg in the tumorous tissues 
of HCC patients. Aside from clarifying whether HBx mRNA is present in such 
tissues or not, the x gene promoter could also be checked for alterations such as 
mutations, deletions and hypermethylations. 
2. Our results have shown that the growth rate of cells transfected with mutant HBx 
gene is lower than those transfected with the wild-type gene. Is this due to growth 
inhibition, induction of cell death or both? For cell growth inhibition, 
investigating whether the cell cycle is blocked using cyclin-specific antibodies 
coupled with flow cytometry could be done to provide answers. As for cell death, 
is it mediated via apoptosis? Checking for DNA nucleosomal ladder combined 
with the use of TUNEL assay, antibodies which stain for Annexin V and/or 
caspase inhibitors may help clarify this issue. 
3. Do mutant and wild-type HBx genes have different transactivating properties? A 
series of different viral and/or cellular gene promoters could be ligated into 
reporter vectors to see if they transactivate promoters differently. On the other 
hand, the newly developed microarray technique can also be used to study the 
differential expression of cellular and viral genes. 
4. Mutations in codons 127, 130 and 131 of the HBx gene are commonly found in 
patients with chronic hepatitis. However, HBX proteins with or without such 
mutations do not seem to differ functionally. Is it possible that these mutations 
affect other HBV genes such as the core gene? 
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Al Recipes of Reagents Used in this Study 
Ampicillin, 50 mg/ml 
Dissolve 250 mg ampicillin in 5 ml double distilled water 
Filter sterilize through a 0.22 \im filter 
Aliquot into 0.5 ml fractions 
Store at-20 °C 
Avoid repeated thawing 
Aqueous prehybridization/hybridization (APH) Solution 
5x SSC (see below) 
5x Denhardt solution (see below) 
1 % (w/v) SDS (see below) 
Add 100 ^ig/ml denatured salmon sperm DNA before use 
Calcium Chloride, 1 M 
Dissolve 54 g of CaCl^ ^GHzO in 200 ml Milli-Q H2O 
Filter sterilize through 0.22 \xm filter 
Citrate Buffer，10 mM, pH 6.0 
Dissolve 3.84 g citric acid (anhydrous) in 1.8 L dd H2O 
Adjust to pH 6.0 using 5M NaOH (see below) 
Adjust to 2 L with dd H2O 
Denaturation Solution 
0.5 M NaOH (see below) 
1.5 M NaCl (see below) 
Denhardt Solution, lOOx 
lOgFicoll 400 
10 g polyvinylpyrrolidone 
10 g bovine serum albumin (Pentax Fraction V) 
Adjust to 500 ml with dd H p 
Filter sterilize using a 0.45 jim filter and store at -20 °C 
Digestion Buffer 
100 mM NaCl (see below) 
10 mM Tris-Cl，pH 8.0 (see below) 
25 mM EDTA, pH 8.0 (see below) 
0.5 % (w/v) SDS (see below) 
0.1 mg/ml proteinase K 
Ethidium Bromide 10 mg/ml 
Dissolve 0.2 g ethidium bromide in 20 ml dd H2O 
Mix well and store in the dark 
109 
EDTA，0.5 M，pH 8.0 
Dissolve 186.1 g of EDTA (disodium salt: dihydrate) in 700 ml dd H2O 
Adjust to pH 8.0 with 10 M NaOH (see below) 
Add dd H2O to 1 liter 
HCl, 1 M 
Mix in the following order: 
913.8 ml dd H^O 
86.2 ml concentrated HCl 
IPTG, 200 mg/ml 
Dissolve 2 g IPTG in 8 ml of dd H2O 
Adjust to 10 ml with dd H2O 
Filter sterilize through a 0.22 x^m filter 
Aliquot into 1 ml fractions 
Store at-20 °C 
Kanamycin, 10 mglml 
Dissolve 100 mg kanamycin in 10 ml dd H2O 
Filter sterilize through a 0.22 \im filter 
Aliquot into 1 ml fractions 
Store at-20 °C 
Avoid repeated thawing 
LB Medium 
Add 20 g LB medium powder into 1 L of dd H2O 
Autoclave at 120 °C for 20 minutes 
NaCl, 3 M 
Dissolve 175.32 g of NaCl in 800 ml of dd H2O 
Adjust to 1 L 
NaOH, 5 M 
Dissolve 200 g of NaOH in 800 ml dd H^O 
Adjust to 1 L 
NaOH, 10 M 
Dissolve 400 g of NaOH in 800 ml dd H2O 
Adjust to 1 L 
Neutralization Solution 
0.5 M Tris-Cl, pH 7.4 (see below) 
1.5 M NaCl (see below) 
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Paraformaldehyde in PBS, 4% (w/v) � 
Dissolve 4 g of paraformaldehyde in 100 ml PBS at 6 5 � C 
Cool to room temperature and filter through a 0.45 \im filter 
Prepare fresh each week 
SDS, 10 % 
Dissolve 100 g SDS in 900 ml dd H2O at 6 8 � C 
Adjust to pH 7.2 with a few drops of concentrated HCl 
Adjust to 1 L 
SSC 20x 
，Dissolve 175.3 g of NaCl and 88.2 g of sodium citrate (trisodium salt: dihydrate) 
in 800 ml dd 邸 
Adjust pH to 7.0 with 1 M HCl (see above) 
Adjust to 1 L with dd H2O 
TE Buffer, pH 8.0 
10 mM Tris-Cl，pH 8.0 (see below) 
1 mM EDTA，pH 8.0 (see above) 
Tris-Cl, 1 M, pH 7,4 
Dissolve 121.1 g of Tris Base in 800 ml dd H2O 
Adjust to pH 7.4 with concentrated HCl 
Cool to room temperature and make final adjustments to the pH 
Adjust to 1 L with dd H2O 
Tris-Cl, 1 M, pH 8.0 
Dissolve 121.1 g of Tris Base in 800 ml dd H2O 
Adjust to pH 8.0 with concentrated HCl 
Cool to room temperature and make final adjustments to the pH 
Adjust to 1 L with dd H2O 
X-Gal, 20 mg/ml 
Dissolve 200 mg in 10 ml dimethlyformamide 
Aliquot into 1 ml fractions 
Wrap in aluminium foil 
Store a t -20°C 
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A2 Schematic Diagram of Downward Capillary Transfer of DNA 
r 
Sponge soaked in 10x SSC J 1 V � 
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